Document:

exv10w38

 

Exhibit 10.38

***Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

Non-Exclusive Product License Agreement

     This Non-Exclusive Product License Agreement (“Agreement”) is made and entered into
effective as of November 3, 2003 (the “Effective Date”), by and between Cambridge Antibody
Technology Limited, having its principal offices at The Milstein Building, Granta Park,
Cambridgeshire CB 1 6GH, England (“CAT”), and Micromet AG, having its principal offices at
Staffelseestrasse 2, 81477 Munich, Germany (“Licensee”). CAT and Licensee each may be referred to
herein individually as a “Party,” or collectively as the “Parties.”

     Whereas, the Parties have entered into that certain Research Cross-License Agreement
dated as of September 3, 2003 (the “Research Cross-License Agreement”), under which Licensee may
elect to receive licenses under the CAT Licensed Patents (as defined below) for the purpose of
developing and commercializing antibody products towards specified targets;

     Whereas, Licensee has elected to receive such a license for the purpose of developing
and commercializing antibody products towards the GM-CSF target; and

     Whereas, CAT desires to grant a license to Licensee on a non-exclusive basis of the
right to use the CAT Licensed Patents for the purpose of developing and commercializing such
products in respect of such target.

     Now, Therefore, in consideration of the premises and the mutual covenants
and agreements herein contained, the Parties agree as follows:

1. Definitions

     When used in this Agreement, capitalized terms will have the meanings as defined below and
throughout the Agreement.

     1.1 “Affiliate” means a legal entity that, directly or indirectly, through one or more
intermediaries, controls, is controlled by, or is under common control with a Party. For purposes
of this definition only, “control” and, with correlative meanings, the terms “controlled by” and
“under common control with” means (a) the possession, directly or indirectly, of the power to
direct the management or policies of a legal entity, whether through the ownership of voting
securities or by contract relating to voting rights or corporate governance, or (b) the ownership,
directly or indirectly, of more than 50% of the voting securities or other ownership interest of a
legal entity; provided that, if local law restricts foreign ownership, control will be established
by direct or indirect ownership of the maximum ownership percentage that may, under such local law,
be owned by foreign interests.

     1.2 “Antibody” means a molecule or gene encoding such a molecule comprising or

1.

 

containing more than one immunoglobulin variable domain or parts of such domain or any
existing or future fragments, variants, modifications or derivatives thereof.

     1.3 “Antigen” means any structure, including an entire protein, post-translational
modifications, lipids, or glyco-lipids, for which Antibody variable domains have binding affinity.

     1.4 “BiTE Product” means any composition or formulation containing or comprising a bi-specific
Single Chain Antibody, wherein one arm of the Single Chain Antibody binds to T-cells.

     1.5 “Business Day” means any day (other than a Saturday or Sunday) upon which major commercial
banks are open for business in the cities of London and Munich.

     1.6 “CAT Background Know-How” means the Know-How Controlled by CAT relating to the CAT
Licensed Patents and described in Schedule II, which the Parties may amend from time to
time at their sole discretion in accordance with Section 2.4.

     1.7 “CAT Licensed Patents” means (a) those Patents identified in Schedule I, and (b)
any Patents that claim or cover any CAT Phage Display Improvements and that are selected by
Licensee for inclusion pursuant to Section 9.2.

     1.8 “CAT Phage Display Improvements” means any Improvement of a Phage Display process or any
other technology, process, or methodology (each as claimed in or covered by either of the CAT
Licensed Patents or CAT Background Know-How) that satisfies all of the following criteria: (a) is
first conceived or reduced to practice within [***] of the Effective Date; provided,
however, that upon the request of Licensee at any time during the [***] period following
the date that is [***] from the Effective Date and upon demonstration by Licensee of good
commercial, technical, or legal reasons for extension of the foregoing [***] period, the Parties
agree to negotiate in good faith the potential extension of such period for one (1) additional
[***] period, with the consent by CAT to such extension not to be withheld absent demonstration of
good commercial, technical, or legal reasons for opposing such extension; and (b) is developed by
or on behalf of CAT or its Affiliates; provided, however, that the foregoing will
exclude in respect of CAT only any such improvement, modification or adaptation to the extent that
CAT is not permitted to disclose, license or sublicense such improvement, modification or
adaptation to Licensee as a result of an obligation of CAT to a Third Party.

     1.9 “Combination Product” means any product manufactured or sold by or on behalf of Licensee
in the Field which contains a Licensed Product and one or more other [***].

     1.10 “Controlled” or “Controls” means, with respect to any Know-How, Patent, or other
intellectual property right, possession of the right, whether directly or indirectly, and whether
by ownership, license or otherwise, to assign, or grant a license, sublicense or other right to or
under, such Know-How, Patent or right as provided for herein without violating the terms of any
agreement or other arrangements with any Third Party.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

2.

 

     1.11 “Development” means any development work carried out on a Lead directed towards eventual
commercialization of such Lead as a Licensed Product.

     1.12 “Diagnostic Licensed Product” means any Licensed Product (including a composition,
formulation, device, assay or other product, but excluding Microarrays (as defined in Schedule
V)) (a) for sale as an in vitro or in vivo diagnostic for use in or in relation to humans, or
(b) for sale separately from but in support of a therapeutic product for use in or in relation to
humans.

     1.13 “Dossier” means a written summary setting forth a brief description of the proposed use,
application or clinical indication of a particular product composition or formulation applicable to
the Target Program and its origin, amino acid sequence, nucleotide sequence and Genbank or other
accession number (if available); provided, however, that the foregoing will exclude
any information that is subject to an obligation of confidentiality between Licensee and a Third
Party.

     1.14 “Excluded Field” means the field of research and development as set out in Schedule
IV.

     1.15 “Excluded Technology” means the applications and technologies as set out in Schedule
V.

     1.16 “Exploit” or “Exploitation” means to make, have made, import, export, use, sell, offer
for sale, or otherwise dispose of a product, including all discovery, research, development,
registration, modification, enhancement, improvement, manufacture, storage, formulation,
exportation, transportation, distribution, promotion and marketing activities related thereto.

     1.17 “FDA” means the United States Food and Drug Administration, or any successor agency
thereto having the administrative authority to regulate the marketing of human pharmaceutical
products or biological therapeutic products, delivery systems and devices in the United States of
America.

     1.18 “Field” means the prognosis, diagnosis, prophylaxis or treatment of human diseases or
conditions by modulation of the Target; provided, however, that the foregoing will
exclude the Excluded Field.

     1.19 “Gatekeeping
Procedure” means the process by which [***] whether, with respect
to a [***], prior to a [***], (a) such [***] or which [***] or (b) [***].

     1.20 “Improvement” means any improvement, modification or adaptation of any technology,
process or methodology each as claimed in or covered by either of the CAT Licensed Patents or CAT
Background Know-How, as applicable, which may be developed by or on behalf of a Party, its
sublicensees or its Affiliates during the Term.

     1.21 “Insolvency Event” means, except for the event of a solvent reorganization or
amalgamation, (i) the filing by a Party in court or agency pursuant to any applicable statute or

 

			
	***	 	Certain information on the page has been omitted and filed
separately with the Commission. Confidential treatment has been
requested with respect to the omitted portions.

3.

 

regulation of any state or country, a petition in bankruptcy or insolvency or for
reorganization or for an arrangement or for the appointment of a receiver or trustee of a Party or
of its assets, or (ii) the filing by a Third Party against a Party of an involuntary petition in
bankruptcy or seeking reorganization, liquidation, dissolution, winding up arrangement, composition
or readjustment of such Party’s debts or any other relief under any bankruptcy, insolvency,
reorganization or other similar act or law of any jurisdiction now or hereafter in effect, or the
issuance of a warrant of attachment, execution or similar process against a Party, and, in each
case, only if the applicable petition, warrant of attachment, execution or similar process is not
dismissed within ninety (90) days after the filing thereof, or (iii) if any Party proposes or is a
Party to any dissolution or liquidation under applicable law, or makes an assignment for the
benefit of creditors.

     1.22 “Know-How” means all non-public inventions, data, information, methods, procedures,
processes and materials, including but not limited to, biological, chemical, biochemical,
toxicological, pharmacological, metabolic, formulation, clinical, analytical and stability
information and data (other than such Know-How which is or becomes the subject of a patent or of a
provisional or filed patent application or which otherwise becomes public).

     1.23 “Lead” means an Antibody that is selected from a pool of Antibodies against the Target
and that has been generated by Phage Display, in relation to which the Licensee carries out further
development including, but not limited to, lead optimization.

     1.24 “Licensed Product” means any product, substance or formulation arising from the Target
Program, and (a) the Development, manufacture, importation, use or sale of which would but for the
provisions of this Agreement infringe one or more Valid Claims under the CAT Licensed Patents, or
(b) which utilizes the CAT Background Know-How.

     1.25 “Licensee Phage Display Improvement” means any Improvement of a Phage Display process or
any other technology, process, or methodology that is developed by or on behalf of Licensee, its
Affiliates or sublicensees and that satisfies all of the following criteria: (a) is first reduced
to practice, or described in a patent application, publication, or abstract within [***] after the
Effective Date; provided, however, that upon the request of CAT at any time during
the [***] period following the date that is [***] from the Effective Date and upon demonstration by
CAT of good commercial, technical, or legal reasons for extension of the foregoing [***] period,
the Parties agree to negotiate in good faith the potential extension of such period for one (1)
additional[***] period, with the consent by Licensee to such extension not to be withheld absent
demonstration of good commercial, technical, or legal reasons for opposing such extension; (b) may
not lawfully be Exploited without a license to one or more Valid Claims within the CAT Licensed
Patents; (c) is not a human therapeutic or diagnostic product, a manufacturing method applicable to
that product, or a method of using that product; and (d) is not claimed in or covered by any Patent
Controlled by Licensee and is not an improvement, modification or adaptation of any such invention;
and (e) does not relate to any BiTE Product.

     1.26 “MAA” means a marketing approval application filed with the European Medicines Evaluation
Agency or a Biologics License Application filed with the FDA, and any

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

4.

 

corresponding applications in other countries or territories.

     1.27 “Major Market Country” means the [***].

     1.28 “Marketing Approval” means the approval of an MAA for a Licensed Product and any pricing
and reimbursement approvals to the extent the applicable Regulatory Authorities in a country
require a pricing or reimbursement approval prior to the marketing and sale of such Licensed
Product in such country.

     1.29 “[***] Agreement” means that certain license agreement by and between [***] and CAT dated
as of [***], as may be then in effect, pursuant to which CAT is the exclusive licensee of certain
of the CAT Licensed Patents and certain other Know-How related thereto.

     1.30 “Net Sales” means the gross amount invoiced by Licensee, its Affiliate or its sublicensee
for sales of Licensed Products to any Third Party (and in all cases amounts actually received to
the extent not invoiced), less any (a) normal trade, cash and quantity discounts actually allowed,
including charge backs; (b) amounts allowed for returned or defective Licensed Products; (c)
insurance and transportation charges to the extent included in the invoiced amount; and (d) custom
duties, VAT, sales taxes or other governmental charges paid in connection with such sales (but
excluding what is commonly known as income taxes). Any of the deductions listed above that involves
a payment by Licensee, its Affiliate or sublicensee will be taken as a deduction in the calendar
quarter in which the payment is actually made by such entity; provided, however, to
the extent that the aggregate of such deductions in any calendar quarter for a Licensed Product
exceeds the gross amount invoiced by Licensee, its Affiliate or its sublicensee for sales of such
Licensed Product, then Licensee may carry forward any excess amounts and reduce the gross amounts
invoiced in connection with the applicable sale of Licensed Products in one or more subsequent
calendar quarter(s).

     Any amounts received on account of transfers of Licensed Products between Licensee, its
Affiliates or sublicensees of Licensed Products hereunder will be excluded from the calculation of
Net Sales, and Net Sales will be calculated based on the final sale of such Licensed Product by
Licensee, its Affiliates or sublicensees to any Third Party.

     In the event a Licensed Product is sold in the form of a Combination Product, Net Sales for
purposes of royalty payments on the Combination Product will be calculated by multiplying the Net
Sales of the Combination Product by the fraction A/(A+B), where A is the invoice price of the
Licensed Product if sold separately (i.e., without the other active ingredients or components) by
Licensee, its Affiliate or sublicensee; and B is the aggregate invoice price of the other active
ingredients or components in the Combination Product, if sold separately by Licensee, its Affiliate
or sublicensee. In the event that no such separate sales are made by Licensee, its Affiliate or
sublicensee, then Net Sales for purposes of royalty payments on the Combination Product will be
calculated by multiplying the Net Sales of the Combination Product by the fraction C/(C+D) where C
is the fully allocated cost of the Licensed Product taken separately from the Combination Product
(i.e., not including the other active ingredients or

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

5.

 

components); and D is the aggregate fully allocated cost of the other active ingredients or
components; in each case, such costs being determined using generally accepted accounting
procedures consistently applied by Licensee, its Affiliate or sublicensee, as applicable.

     1.31 “Non-Adjusted Royalty Rate” means with respect to any Licensed Product the rate equal to
the sum of the maximum royalty rates payable by Licensee to CAT and Third Parties on net sales (as
defined in the applicable agreements) with regard to the sale or other disposition of such Licensed
Product in accordance with the terms and conditions of this Agreement.

     1.32 “Patents” means (a) all patents and patent applications in any country or supranational
jurisdiction, and (b) any substitutions, divisions, continuations, continuations-in-part, reissues,
renewals, registrations, confirmations, re-examinations, extensions, supplementary protection
certificates and the like, and any provisional applications, of any such patents or patent
applications.

     1.33 “Phage Display” means the technology, process or methodology whereby Antibodies are
cloned, expressed, produced and screened on the surface of filamentous bacteriophage.

     1.34 “Phase I Clinical Trial” means, as to a specific Licensed Product, the first controlled
and lawful study in humans of the safety of such Licensed Product, which is prospectively designed
to generate sufficient data (if successful) to commence a Phase II clinical trial (or foreign
equivalent) of such Licensed Product, as further defined in Federal Regulation 21 C.F.R. 312.21.

     1.35 “Primary Application” means a major application of a product containing an Antibody
binding to a target, as ascertained at the time of assessment of such Antibody as a potential
Licensed Product using objective and reasonable scientific and/or commercial criteria data and/or
information. Primary Application does not mean any minor or incidental application.

     1.36 “Regulatory Authorities” means the European Medicines Evaluation Agency, the FDA, any
successor agencies thereto, and any equivalent health regulatory authorities in any applicable
country or territory.

     1.37 “Single Chain Antibody” means an Antibody having binding affinity for an Antigen whereby
such Antibody comprises (i) a polypeptide segment having a light chain variable region, (ii) a
polypeptide having a heavy chain variable region, and (iii) at least one peptide linker linking
those polypeptides into a single chain polypeptide.

     1.38 “Target” means the whole or part and natural variants of the granulocyte-macrophage
colony stimulating factor (GM-CSF) identified by the SWISS-PROT entry name CSF2_HUMAN and accession
number P04141 with the amino acid sequence as set out in Schedule III which is specifically
recognized by an Antibody binding to the foregoing.

     1.39 “Target Program” means (a) the discovery of Antibodies binding to the Target by
practicing inventions claimed in any CAT Licensed Patents or utilizing the CAT Background Know-How;
and (b) development of Antibodies binding to the Target by practicing inventions

6.

 

claimed in any CAT Licensed Patents or utilizing the CAT Background Know-How.

     1.40 “Term” has the meaning assigned to it in Section 10.1.

     1.41 “Therapeutic Licensed Product” means any Licensed Product for which Marketing Approval is
sought or received for therapeutic or prophylactic use in humans.

     1.42 “Third Party” means any party other than CAT, Licensee or their respective Affiliates.

     1.43 “Valid Claim” means (i) any claim of an issued and unexpired patent within the CAT
Licensed Patents which has not been held unenforceable or invalid by a court or other governmental
agency of competent jurisdiction in a decision that is not appealed or cannot be appealed, and
which has not been disclaimed or admitted to be invalid or unenforceable through reissue or
otherwise, or (ii) a pending claim in a pending patent application within the CAT Licensed Patents.
Notwithstanding the foregoing clause (ii), in the event that a pending claim in a pending patent
application does not issue as a valid and enforceable claim in an issued patent within [***] after
the earliest date from which such patent application claims priority, such a pending claim will not
be a Valid Claim, unless and until such pending claim subsequently issues as a valid and
enforceable claim in an issued patent, in which case such claim will be reinstated and be deemed to
be a Valid Claim as of the date of issuance of such patent.

2. Grant Of Licenses

     2.1 License. Subject to the terms and conditions of this Agreement, CAT hereby grants to
Licensee a nonexclusive, worldwide, royalty-bearing license under the CAT Licensed Patents and the
CAT Background Know-How to Exploit Licensed Products in the Field. Subject to the terms and
conditions of this Agreement, Licensee may grant and authorize the grant of further sublicenses
under the foregoing license to any of its Affiliates or to a Third Party; provided,
however, that any such sublicense will be consistent with the terms and conditions of this
Agreement, and will impose on the sublicensee the obligations of Licensee and grant CAT the rights
contained in Sections 5.5, 7, 8.3 and 9.1 of this Agreement. Licensee will provide CAT with the
identity of each Third Party licensee of Licensee that receives a sublicense of the rights under
this Section 2.1 within thirty (30) days of execution of the applicable agreement. The Parties
understand and agree that the terms and conditions of this Section 2.1 (including the right to
sublicense and authorize further sublicenses) will apply to any product, composition, or
formulation upon the submission by Licensee of a Dossier for such product pursuant to Section
3.1.1. Licensee hereby covenants and agrees not to use or sublicense any of its rights under the
foregoing license except as expressly permitted in this Agreement.

     2.2 Reservation of Rights. Except for the rights specifically granted herein, CAT reserves
all rights to all CAT Licensed Patents and the CAT Background Know-How Controlled by it and
reserves the right to utilize or allow Third Parties to utilize the CAT Licensed Patents and the
CAT Background Know-How consistent with the terms of this Agreement. No implied licenses are
granted under this Agreement.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

7.

 

     2.3 Excluded Technology. Notwithstanding anything in this Agreement to the contrary, CAT
grants no rights to Licensee under this Agreement (a) to research, develop, manufacture, use, or
sell Licensed Products using the Excluded Technology set forth in items [***] of Schedule
V, or (b) to develop, manufacture, use, or sell any Licensed Product that is a Research Product
or Microarray, as those terms are defined in Schedule V. CAT will notify Licensee promptly
if:

               (a) CAT ceases to be bound by the Excluded Field restriction pursuant to its agreement with
[***] dated [***]; or

               (b) CAT no longer needs to exclude Research Products from the license granted hereunder
pursuant to its agreement with [***] dated [***] (the “[***] License Agreement”), a copy of which
has been provided to Licensee by CAT as of the Effective Date. CAT will promptly notify Licensee of
any modification or amendment to the [***] License Agreement and deliver to Licensee a redacted
copy of any such amended agreement.

     The restrictions set out in this Agreement relating to the Excluded Field or Research Products
set forth above (as the case may be) will, subject to any other restrictions on CAT and to the
provisions of this Agreement, cease to apply from the date of removal of such restriction pursuant
to the terms of the foregoing agreements.

     2.4 Know-How Transfer. Within ninety (90) days after the Effective Date, CAT will disclose in
writing and deliver to Licensee all CAT Background Know-How. CAT may during the Term at its sole
discretion propose to Licensee that additional CAT Background Know-How (developed by or on behalf
of CAT after the Effective Date) be disclosed to Licensee and added to Schedule II.
Licensee will be entitled to accept or reject such additional Know-How at its sole discretion. If
Licensee accepts such additional Know-How, then Schedule II of this Agreement will be
amended in accordance with Section 13.5.

3. Identification Of Licensed Products; Reporting; Diligence

     3.1 Identification of Licensed Products.

          3.1.1 General. Licensee will provide to CAT a Dossier in respect of each Licensed Product
conceived or developed within the Target Program that Licensee desires to Exploit under this
Agreement. During the Term, Licensee will submit such a Dossier to CAT for a particular product
composition or formulation prior to the time Licensee begins administration to humans of such
composition or formulation in a human clinical trial with respect to that product composition or
formulation.

          3.1.2 Confidentiality. CAT will treat all information contained in any Dossier (or update
thereto) provided to CAT under this Section 3.1, or Section 3.3 as Licensee’s Confidential
Information in accordance with the confidentiality provisions of Section 7.

     3.2 Abandonment of a Licensed Product. If at any time during the Term, Licensee

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

8.

 

decides in its discretion that it no longer wishes to Exploit a Licensed Product
itself or with or through an Affiliate or Third Party (an “Abandoned Product”), Licensee will
promptly notify CAT in writing of such decision and any license granted by Section 2.2 of this
Agreement will be deemed to have been terminated solely with regard to such Abandoned Product from
the date Licensee sets forth in such notification. In the case of any Abandoned Product, the
Parties will [***].

     3.3 Dossier Updates. Within [***] Business Days of each anniversary of the Effective Date
during the Term, Licensee will prepare and provide to CAT an update to any Dossier submitted that
summarizes the current status of the research and development regarding each Licensed Product. Such
update may include, by way of example, a brief description of any collaborations, business
transactions, changes of control, publications, conference presentations and intellectual property
or legal matters where such events are relevant to CAT as licensor or Licensee as licensee under
this Agreement, unless such update would constitute a breach by Licensee of a non-disclosure
obligation to a Third Party.

4. Gatekeeping And The Excluded Field

     The Parties hereby acknowledge and agree that the Target has been cleared through CAT’s
Gatekeeping Procedure as of the Effective Date.

5. Payments

     5.1 Initial License Fee. On the Effective Date, Licensee will pay to CAT a non-refundable,
non-creditable license fee of US$[***].

     5.2 Therapeutic Licensed Product Milestone Payments and Royalty Rates. The milestone payments
and royalty rates set forth in this Section 5.2 will apply to each Therapeutic Licensed Product.

          5.2.1 Milestones. Licensee will pay to CAT the following non-refundable, non-creditable
milestone payments for each Therapeutic Licensed Product Exploited by Licensee, its Affiliates or
sublicensees:

	 	 	 
	Milestone Event	 	Milestone Payment
	Initiation of Phase I Clinical Trials for such
Therapeutic Licensed Product in the first Major Market
Country

	 	US$[***]
	 
	 	 
	Acceptance of the filing of the first Marketing Approval
for such Therapeutic Licensed Product in the first Major
Market Country

	 	US$[***]
	 
	 	 
	Receipt of first Marketing Approval for such Therapeutic
Licensed Product in the first Major Market Country

	 	US$[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

9.

 

          5.2.2 Royalties.

               (a) Subject to the terms and conditions of this Agreement, Licensee will pay to CAT a royalty
payment equal to [***]% of Net Sales of each Therapeutic Licensed Product sold by Licensee, its
Affiliates or sublicensees throughout the world. The royalty payment obligation of Licensee under
this Section 5.2.2 will expire on a Therapeutic Licensed Product-by-Therapeutic Licensed Product
and country-by-country basis (in which such Therapeutic Licensed Product is sold) upon the later
of: (a) expiration of the last to expire Valid Claim of the CAT Licensed Patents which, but for the
license granted in this Agreement, would be infringed by the Development, manufacture, importation,
use or sale of such Therapeutic Licensed Product in such country; and (b) ten (10) years from first
commercial sale for use or consumption by the general public of such Therapeutic Licensed Product
by or on behalf of Licensee anywhere in the world. In the event that the period described in clause
(b) of the preceding sentence extends beyond the period described in clause (a) of the preceding
sentence with respect to a Therapeutic Licensed Product in a country (a “Therapeutic Product
Extended Period”), then the royalty rate of [***]% set out above will be reduced to [***]% of Net
Sales of such Therapeutic Licensed Product in such country during such Therapeutic Product Extended
Period.

               (b) Notwithstanding anything herein to the contrary, the Parties agree that no royalties will
be payable by Licensee for a particular country in respect of any Therapeutic Licensed Product
which does not utilize the CAT Background Know-How and which is first sold commercially after the
expiration of the last to expire Valid Claim of the CAT Licensed Patents in such country, which,
but for the license granted in this Agreement, would be infringed by the Development, manufacture,
importation, use or sale of such Therapeutic Licensed Product in such country.

     5.3 Diagnostic Licensed Product Milestone Payments and Royalty Rates. The milestone payments
and royalty rates set forth in this Section 5.3 will apply to each Diagnostic Licensed Product.

          5.3.1 Milestones. Licensee will pay to CAT the following non-refundable, non-creditable
milestone payments for each Diagnostic Licensed Product Exploited by Licensee, its Affiliates or
sublicensees:

	 	 	 
	Milestone Event	 	Milestone Payment
	Acceptance of the filing of the first Marketing Approval
for such Diagnostic Licensed Product in the first Major
Market Country

	 	US$[***]
	 
	 	 
	Receipt of first Marketing Approval for such Diagnostic
Licensed Product in the first Major Market Country

	 	US$[***]

          5.3.2 Royalties.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

10.

 

               (a) Subject to the terms and conditions of this Agreement, Licensee will pay to CAT a royalty
payment equal to [***]% of Net Sales of each Diagnostic Licensed Product sold by Licensee, its
Affiliates or sublicensees, throughout the world. The royalty payment obligation of Licensee under
this Section 5.3.2 will expire on a Diagnostic Licensed Product-by-Diagnostic Licensed Product and
country-by-country basis (in which such Diagnostic Licensed Product is sold) upon the later of: (a)
expiration of the last to expire Valid Claim of the CAT Licensed Patents, which, but for the
license granted in this Agreement, would be infringed by the Development, manufacture, importation,
use or sale of such Diagnostic Licensed Product in such country; and (b) ten (10) years from first
commercial sale for use or consumption by the general public of such Diagnostic Licensed Product by
or on behalf of Licensee anywhere in the world. In the event that the period described in clause
(b) of the preceding sentence extends beyond the period described in clause (a) of the preceding
sentence with respect to a Diagnostic Licensed Product in a country (a “Diagnostic Product Extended
Period”), then the royalty rate of [***]% set out above will be reduced to [***]% of Net Sales of
such Diagnostic Licensed Product in such country during such Diagnostic Product Extended Period.

               (b) Notwithstanding anything herein to the contrary, the Parties agree that no royalties will
be payable by Licensee for a particular country in respect of any Diagnostic Licensed Product which
does not utilize the CAT Background Know-How and which is first sold commercially after the
expiration of the last to expire Valid Claim of the CAT Licensed Patents in such country, which,
but for the license granted in this Agreement, would be infringed by the Development, manufacture,
importation, use or sale of such Diagnostic Licensed Product in such country.

          5.3.3 Acceleration of Milestones. If the first commercial sale of a Diagnostic Licensed
Product by Licensee, its Affiliate or sublicensee is made in a Major Market Country where no
Marketing Approval has been granted for such Licensed Product, then both of the milestone payments
set forth in Section 5.3.1 will be payable as if the relevant milestone events had occurred as of
the date of such first commercial sale.

     5.4 Payment.

          5.4.1 Payment of Milestones. Upon Licensee achieving a development milestone that triggers a
milestone payment obligation pursuant to Sections 5.2.1 or 5.3.1, Licensee will give notice to CAT
within [***] days of achieving each milestone, and will make the corresponding milestone payment
within [***] days of the achievement of the corresponding milestone event.

          5.4.2 Payment of Royalties. For any quarterly period for which royalties are payable by
Licensee to CAT under Sections 5.2.2 or 5.3.2, Licensee will provide notice to CAT within [***]
days after the end of each such calendar quarter and a written report with Licensee’s good faith
estimate of Net Sales accrued in the preceding calendar quarter and the royalties payable thereon.
Licensee will make royalty payments to CAT for Licensed Products or

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

11.

 

Diagnostic Licensed Products sold during a calendar quarter within [***] days of the last day
of that calendar quarter. Each royalty payment will be accompanied by a written report for that
calendar quarter showing the cumulative Net Sales of the applicable product sold by Licensee, its
Affiliates and its sublicensees on a country-by-country basis worldwide during the quarterly
reporting period and the corresponding royalties payable under this Agreement.

          5.4.3 Payment Method. All amounts due hereunder will be paid in US Dollars by wire transfer
in immediately available funds to Barclays Bank Plc, Benet Street Business Centre, P O Box No 2,
Cambridge, CB2 3PZ, England, Account Number [***]; Sort Code: [***], Swift Code: [***] (payments
may be routed through Barclays Bank Plc, New York, ABA Routing Code: [***]; Swift Code: [***]) or
such other bank account as CAT may from time to time notify Licensee. Any payments or portions
thereof due hereunder which are not paid on the date such payments are due will bear interest from
the due date until the date of payment at the rate which is the lower of (i) [***]percentage points
above the overnight London Interbank Offering Rate in effect on the due date or (ii) the highest
rate permitted by applicable law.

          5.4.4 Currency Conversion for Milestone Payments and Calculation of Net Sales. For any
currency conversion required in connection with any payment hereunder, or in determining the amount
of royalties due, such conversion will be made at the prevailing commercial rate of exchange for
purchasing the currency into which an amount is to be converted as publicly announced as the spot
rate quoted by Barclays Bank Plc (or its successor) in London on (i) the day which is fifteen (15)
Business Days following the date of the achievement of any milestone for which payment is due
pursuant to Sections 5.2.1 or 5.3.1 and (ii) the day which is the last Business Day of the
applicable quarterly period for any royalty payments made pursuant to Sections 5.2.2 or 5.3.2. For
purposes of determining the amount of royalties due, the amount of Net Sales in any foreign
currency will be computed by converting such amount into US Dollars as provided in this Section.
All payments due under this Agreement will be paid exclusive of value added tax.

          5.4.5 Credit for Royalties Paid on Uncollected Amounts. As set forth in this Section 5.4.5,
Licensee will be entitled to a credit for royalties paid by Licensee hereunder with respect to any
invoiced amounts that are included in Net Sales but are not collected by Licensee, its Affiliate or
sublicensee, as applicable (each such amount, an “Uncollected Amount”). Such credit may be taken in
the calendar quarter in which the applicable Uncollected Amount is no longer recorded as a
receivable or in one or more subsequent calendar quarter(s) to the extent that such credit exceeds
the amount payable by Licensee to CAT in any calendar quarter. The amount of such credit will be
equal to the difference between (x) the royalty actually paid by Licensee to CAT hereunder for the
Uncollected Amount, and (y) the royalty actually paid by CAT to [***], its successors or assigns
pursuant to the [***] Agreement for the Uncollected Amount. Upon the request of Licensee in
connection with this Section 5.4.5, CAT will provide to Licensee payment records supporting payment
to [***] by CAT in respect of such Uncollected Amount. Licensee agrees that an Uncollected Amount
will only be recorded as not receivable once Licensee has used its reasonable endeavors to recover
such amount from the relevant Third Party in accordance with its usual practice for recovering
unpaid debts. To the extent that an

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

12.

 

Uncollected Amount recorded as not receivable is in fact subsequently received by Licensee,
Licensee will pay to CAT the corresponding amount of any credit previously taken by Licensee in
accordance with Section 5.4.2.

     5.5 Records; Audits. Licensee will at all times keep or cause or procure to be kept and for
at least [***] retain accurate data, accounts and supporting documentation of all Licensed Products
produced and/or sold, used or disposed of by or on behalf of Licensee and the Net Sales thereof
(collectively, “Records”) to the extent such Records are reasonably required for the computation
and verification of royalties and all other sums payable under this Agreement. Licensee will give
to or procure for CAT’s nominated representative, upon reasonable request in writing and no more
than [***], access to Licensee’s facilities during normal business hours to inspect all Records
kept in accordance with this Section 5.5 and to make copies or to take extracts from these Records.
However, CAT’s nominated representative will not disclose to CAT or any Third Party any
Confidential Information belonging to Licensee but will merely report on any under or over payment
discovered as a result of his inspection. CAT will bear all costs of such audit, unless the audit
reveals an underpayment of more than [***]% from payments otherwise due and payable hereunder, in
which case Licensee will bear the cost of the audit.

     5.6 Payment of Additional Amounts. If, based on the results of any audit, additional payments
are owed to CAT under this Agreement, Licensee will make such additional payments promptly after
the accounting firm’s written report is delivered to both Parties. If, based on the results of any
audit, payments made by Licensee pursuant to Sections 5.2 or 5.3 exceeded payments indicated by the
audit as being due thereunder, such excess will be credited against future amounts owed by Licensee
under Sections 5.2 or 5.3.

     5.7 Confidentiality. CAT will treat all information provided to it pursuant to any audit
performed under Section 5.5 in accordance with the confidentiality provisions of Section 7 and will
cause its accounting firm or other designated representative to enter into a reasonably acceptable
confidentiality agreement with Licensee obligating such firm or representative to maintain all such
financial information in confidence pursuant to such confidentiality agreement.

     5.8 Withholdings.

          5.8.1 Licensee will be entitled (if required to do so) to deduct tax from the payments it
makes to CAT under this Section 5 above (“Withholding Tax”) provided that:

               (a) Licensee will pay over such Withholding Tax to the relevant revenue authority and will
provide to CAT such documentary evidence as CAT may reasonably require regarding (i) the amount so
deducted, and (ii) evidence of payment to such authority; and

               (b) Licensee will provide to CAT such assistance as CAT may reasonably require (including
submission of documents to relevant revenue authorities) to obtain a repayment of the Withholding
Tax or (as the case may be) to obtain the benefit of such Withholding Tax whether by credit against taxes or otherwise.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

13.

 

          5.8.2 If, pursuant to a relevant double taxation agreement, a Party has the right to claim
relief (whether in whole or in part) from any Withholding Tax, then:

               (a) Licensee will co-operate with CAT in seeking a written direction from the relevant revenue
authorities to the effect that either: (i) no Withholding Tax should be operated in respect of
payments under this Agreement, or (ii) the rate of Withholding Tax will be such lower rate as
specified by the relevant revenue authority, and Licensee will comply with any such direction
given; and

               (b) pending such written direction, Licensee will deduct Withholding Tax in accordance with
Section 5.8.1 above, but will, in addition to the sums otherwise payable under this Agreement, pay
to CAT such further sum as will ensure that, after operation of Withholding Tax on all such sums,
the net amount received by CAT equals the amount that CAT would have received had the relevant
revenue authority already issued the written direction described in Section 5.8.2(a)(i) above or,
as the case may be, Section 5.8.2(a)(ii) above.

          5.8.3 If, as a result of any change in corporate status or location of CAT, or permitted
assignment of this Agreement by CAT, Withholding Tax becomes due on payments from Licensee to CAT
or its permitted assignee and CAT is not able to claim a credit or reimbursement for such tax, in
whole or in part, then any amount of Withholding Tax deducted by Licensee on amounts payable by
Licensee to CAT hereunder will be treated as if the amount of Withholding Tax was paid directly to
CAT, to the extent that a credit or reimbursement could not be claimed by CAT.

          5.8.4 If, as a result of any change in corporate status or location of Licensee, or permitted
assignment of this Agreement by Licensee, Withholding Tax becomes due on payments from Licensee to
CAT or its permitted assignee and CAT is not able to claim a credit or reimbursement for such tax,
in whole or in part, then Licensee will deduct Withholding Tax in accordance with Section 5.8.1
above, but will, in addition to the sums otherwise payable under this Agreement, pay to CAT such
further sum as will ensure that, after operation of Withholding Tax on all such sums, the net
amount received by CAT equals the amount that CAT would have received had the non-creditable or
non-deductible amount of such Withholding Tax not been deducted. To the extent that any such amount
deducted by Licensee in accordance with this Section 5.8.4 is in fact subsequently able to be
claimed by CAT as a credit or reimbursement for such tax otherwise deducted, then CAT will pay to
Licensee the corresponding amount of any such credit or reimbursement for such tax otherwise
eligible to be deducted by CAT.

6. Representation And Warranties; Covenants

     6.1 Representations of CAT. CAT represents to Licensee that as of the Effective Date: (a) it
Controls the CAT Licensed Patents and the CAT Background Know-How licensed under this Agreement
(subject to the restrictions described in Section 2.3 above); (b) the CAT Licensed Patents includes
all Patents relating to Phage Display that both (i) are owned by
CAT or are licensed from the [***] to CAT, and (ii) would be infringed by Licensee’s
performance of

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

14.

 

activities in the Field or the Development, manufacture, importation, use or sale of
Antibody Products resulting from such activities; provided, however, that it will
not be a breach of the foregoing representation if CAT has in good faith inadvertently omitted a
Patent from Schedule I and is not otherwise in breach of its covenant under Section 6.3
regarding such Patent; (c) except as disclosed on Schedule VI, it has not received any
written communication that expressly threatens interference actions or oppositions to any Patents
‘within the CAT Licensed Patents or other litigation before any patent office, court, or any other
governmental entity in any jurisdiction in regard to the CAT Licensed Patents; (d) except as
disclosed on Schedule VI, it has not been served with any complaint alleging infringement
of a Third Party’s patents arising from the practice of the claims in the Patents within the CAT
Licensed Patents; and (e) Schedule VI includes a complete list of all pending claims of
Third Parties in regard to the entitlement, validity or enforceability of the CAT Licensed Patents.

     6.2 Reciprocal Representations and Warranties. Each Party represents and warrants to the
other Party that: (a) this Agreement is a legal and valid obligation binding upon its execution and
enforceable against it in accordance with its terms and conditions; and (b) the execution, delivery
and performance of this Agreement by such Party has been duly authorized by all necessary corporate
action, and the person executing this Agreement on behalf of such Party has been duly authorized to
do so by all requisite corporate actions.

     6.3 Additional Covenants. CAT hereby covenants and agrees that (a) it will maintain
throughout the Term all agreements with Third Parties granting CAT rights in and to the CAT
Licensed Patents and CAT Background Know-How that are necessary to grant Licensee the licenses
granted in Section 2 of this Agreement (including, without limitation, the [***] Agreement) and (b)
it will promptly upon discovery of any omission amend Schedule I as of the Effective Date
to include any Patent omitted from Schedule I.

     6.4 DISCLAIMER OF WARRANTY. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT,
EACH PARTY MAKES NO REPRESENTATIONS AND GRANTS NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR
BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND CAT AND LICENSEE EACH SPECIFICALLY DISCLAIMS ANY
OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF
QUALITY, OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY
INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

7. Confidentiality

     7.1 Definition. During the Term and subject to the terms and conditions of this Agreement, a
Party (the “Disclosing Party”) may communicate to another Party (the “Receiving
Party”) confidential information in connection with this Agreement or the performance of its
obligations hereunder, including, without limitation, any Dossier or update thereto, any Know-How,
any information regarding CAT Phage Display Improvements or Licensee Phage Display

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

15.

 

Improvements,
any reports provided pursuant to this Agreement, any scientific and manufacturing information and
plans, marketing and business plans, and financial and personnel matters relating to a Party or its
present or future products, sales, suppliers, customers, employees, investors or business
(collectively, “Confidential Information”).

     7.2 Exclusions.

          7.2.1 Notwithstanding the foregoing, information of a Disclosing Party will not be deemed
Confidential Information with respect to a Receiving Party for purposes of this Agreement if such
information:

               (a) was already known to the Receiving Party or its Affiliates, other than under an obligation
of confidentiality or non-use, at the time of disclosure to the Receiving Party;

               (b) was generally available or known to parties reasonably skilled in the field to which such
information or Know-How pertains, or was otherwise part of the public domain, at the time of its
disclosure to the Receiving Party;

               (c) became generally available or known to parties reasonably skilled in the field to which
such information or Know-How pertains, or otherwise became part of the public domain, after its
disclosure to the Receiving Party through no fault of or breach of its obligations under this
Section 7 by the Receiving Party;

               (d) was disclosed to the Receiving Party other than under an obligation of confidentiality or
non-use, by a party other than the Disclosing Party who had no obligation to the Disclosing Party
not to disclose such information or Know-How to others; or

               (e) was independently discovered or developed by the Receiving Party or its Affiliates, as
evidenced by contemporaneous written records, without the use of or reference to, and by personnel
who had no knowledge of or access to, any Confidential Information of the Disclosing Party.

          7.2.2 Specific aspects or details of Confidential Information will not be deemed to be within
the public domain or in the possession of a person or entity merely because the Confidential
Information is embraced by more general information in the public domain or in the possession of
such person or entity. Further, any combination of Confidential Information will not be considered
in the public domain or in the possession of a person or entity merely because individual elements
of such Confidential Information are in the public domain or in the possession of such person or
entity unless the combination and its principles are in the public domain or in the possession of
such person or entity.

     7.3 Disclosure and Use Restriction. Except as expressly provided herein, the
parties agree that, during the Term and for [***] thereafter (unless one or more of the
exceptions described in 7.2.1 apply), the Receiving Party and its Affiliates and sublicensees will
keep

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

16.

 

completely confidential and will not publish or otherwise disclose and will not use fir any
purpose except for the purposes contemplated by this Agreement any Confidential Information of the
Disclosing Party, its Affiliates or sublicensees.

     7.4 Authorized Disclosure. A Receiving Party may disclose Confidential Information of a
Disclosing Party to the extent that such disclosure is:

          7.4.1 made in response to a valid order of a court of competent jurisdiction or other
governmental or regulatory body of competent jurisdiction; provided, however, that
the Receiving Party will first have given notice to the Disclosing Party and given the Disclosing
Party a reasonable opportunity to quash such order and to obtain a protective order requiring that
the Confidential Information and documents that are the subject of such order be held in confidence
by such court or governmental or regulatory body or, if disclosed, be used only for the purposes
for which the order was issued; and provided, further, that if a disclosure order
is not quashed or a protective order is not obtained, the Confidential Information disclosed in
response to such court or governmental order will be limited to that information which is legally
required to be disclosed in response to such court or governmental order;

          7.4.2 otherwise required by law or mandatory regulation; provided, however,
that the Disclosing Party will provide the Receiving Party with notice of such disclosure in
advance thereof to the extent practicable;

          7.4.3 made by the Receiving Party to the regulatory authorities as required in connection with
any application, filing, or similar requests for regulatory approvals; provided,
however, that reasonable measures will be taken to assure confidential treatment of such
information;

          7.4.4 made by the Receiving Party, in connection with the performance of this Agreement, to
Affiliates, permitted sublicensees, employees, consultants, representatives or agents, each of whom
prior to disclosure must be bound by obligations of confidentiality and non-use at least equivalent
in scope to those set forth in this Section 7;

          7.4.5 made by the Receiving Party to existing or potential acquirers or merger candidates,
potential collaborators (to the extent contemplated hereunder), investment bankers, existing or
potential investors, venture capital firms or other financial institutions or investors for
purposes of obtaining financing, each of whom prior to disclosure must be bound by obligations of
confidentiality and non-use at least equivalent in scope to those set forth in this Section 7; or

          7.4.6 a disclosure of the terms of this Agreement and disclosed in accordance with Section
7.6.

     7.5 Use of Name. Neither Party will make public use of the other Party’s name except (i) in
connection with announcements and other permitted disclosures relating to this
Agreement and the activities contemplated hereby, (ii) as required by applicable law, and
(iii) otherwise as agreed in writing by such other Party.

     7.6 Terms of Agreement to be Maintained in Confidence. Subject to the other provisions of
this Section 7 (including the exception for any public disclosures made in

17.

 

compliance with the
terms of this Section 7.6), the Parties agree that the terms of this Agreement are confidential and
will not be disclosed by either Party to any Third Party (except to a Party’s professional advisor)
without advance written permission of the other Party; provided, however, that
either Party may make any filings of this Agreement required by law or regulation in any country so
long as such Party uses its reasonable efforts to obtain confidential treatment for portions of
this Agreement as available, consults with the other Party, and permits the other Party to
participate, to the extent practicable, in seeking a protective order or other confidential
treatment; and provided, further, that either Party may disclose the terms of this
Agreement to a Third Party (and its professional advisors) when such disclosure is reasonably
necessary in connection with (i) the grant of a license or sublicense of the CAT Licensed Patents
to such Third Party, (ii) a merger, acquisition, placement, investment, or other such transaction
with such Third Party, or (iii) the sale of securities to or other financing from such Third Party
or a financing underwritten by such Third Party, in which case disclosure may be made to any person
or entity to whom such Third Party sells such securities (and its professional advisors). Advance
written permission for disclosure will not be required when a Party is ordered to disclose
information concerning the Agreement by a competent tribunal or such disclosures are required by
law, regulation, or stock exchange rules, except that such Party will make all reasonable efforts
to limit any disclosure as may be required in the course of legal proceedings by entry of an
appropriate protective and confidentiality order, and will provide the other Party with as much
advance notice of such circumstances as is practicable.

     7.7 Press Release. Promptly following the Effective Date, the Parties will mutually agree on
whether a press release shall be published and, if applicable, on the text of a press release
announcing the execution of this Agreement. Neither Party will issue a press release announcing
such execution prior to such agreement.

8. Filing, Prosecution And Maintenance Of Patent Rights

     8.1 Prosecution and Maintenance. As between the Parties, CAT will be solely responsible and
bear all costs for the preparation, filing, prosecution and maintenance of the CAT Licensed Patents
in its discretion, subject to the terms and conditions of this Agreement.

     8.2 Costs. As between the Parties, CAT will be solely responsible and bear all costs for (and
enjoy all recovery from) any actions concerning the CAT Licensed Patents, including but not limited
to reexaminations, oppositions, interferences, and infringement actions, all in its sole and
absolute discretion.

     8.3 No Challenge. CAT will be permitted to terminate this Agreement if Licensee or its
Affiliates challenge, or intentionally direct or intentionally assist (other than under compulsion
of a legal process) a third party to challenge, the validity or enforceability of any of the
Patents within CAT Licensed Patents; provided, however, that the foregoing
termination right will not apply in the event that such challenge to a patent within the CAT
Licensed Patents is brought by Licensee or its Affiliates in response to a suit or proceeding on
such patent brought by CAT (or its Affiliates) against Licensee or its Affiliates. If a sublicensee
of Licensee or its Affiliates (or an Affiliate of such sublicensee) challenges the validity or
enforceability of or otherwise opposes any such Patent under which such sublicensee is sublicensed,
then Licensee upon notice by CAT will terminate such sublicense. Licensee and its Affiliates will
include

18.

 

provisions in all agreements that grant sublicense rights under the Patents within CAT
Licensed Patents that if the sublicensee or its Affiliates challenge the validity or enforceability
of or otherwise oppose any such Patents under which the sublicensee is sublicensed, Licensee may
terminate its sublicense agreement with such sublicensee.

     8.4 Notice. CAT will notify Licensee of any successful challenge to the CAT Licensed Patents
by any Third Party and will, upon request by Licensee, provide Licensee with reasonable
documentation regarding any such challenge. Licensee will notify CAT of any infringement by a Third
Party of any Patent in the CAT Licensed Patents of which Licensee becomes aware and will provide
CAT with the available evidence, if any, of such infringement.

     8.5 Enforcement. As between the Parties, CAT will have the exclusive right and sole
discretion during the Term to stop infringement of the CAT Licensed Patents, including by bringing
suit or other proceeding against the infringer in its own name. Upon request by CAT, Licensee will
provide reasonable assistance to CAT as a party to the lawsuit or other proceeding, at CAT’s
expense; provided, however, that CAT will retain control of the prosecution of such
suit or proceeding. CAT will bear all its costs incurred in connection with such lawsuit or other
proceeding, and, consequently, will be entitled to collect and retain for its own account: such
damages and profits as may be accrued as a result of such lawsuit or other proceeding.

9. Improvements; Ownership

     9.1 Phage Display Improvements.

          9.1.1 Disclosure of Licensee Phage Display Improvements. Within [***] following conception or
discovery by or on behalf of Licensee, its Affiliates or sublicensees of any Licensee Phage Display
Improvements, Licensee will provide CAT with notice of such Licensee Phage Display Improvements.

          9.1.2 Ownership. As between the Parties, and subject to the licenses granted in Section
9.1.3, Licensee will retain all right, title and interest in and to any and all Licensee Phage
Display Improvements. Licensee will ensure that to the extent permitted by law, any third party,
including Licensee’s sublicensees, performing work related to Phage Display is under an obligation:
(a) to assign all inventions, Patents, and Know-How relating to any Licensee Phage Display
Improvements to Licensee, or where this obligation is not permitted, (b) to exclusively license all
such inventions, Patents, and Know-How to Licensee, with the right to sublicense, or where neither
of the obligations described in the preceding clause (a) or (b) is permitted, then (c) to
non-exclusively license all such inventions, Patents, and Know-How to Licensee, with the
right to sublicense.

          9.1.3 License to CAT. Subject to the terms and conditions of this Agreement, Licensee hereby
grants to CAT a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid license,
with the right to grant and authorize the grant of sublicenses (in accordance with the terms of
Section 2.1 relating to sublicenses by Licensee, mutatis mutandis), under the Licensee Phage
Display Improvements and any intellectual property rights therein to use and

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

19.

 

practice the Licensee
Phage Display Improvements for the purpose of identifying, producing, developing, making, importing
and selling products (other than BiTE Products) containing or comprising one or more Antibodies or
for any other purpose. CAT hereby covenants and agrees not to use or sublicense any of its rights
under the foregoing license except as expressly permitted in this Agreement. The license set forth
in this Section 9.1.3 will survive expiration or termination of this Agreement, except if this
Agreement (or, after expiration or termination of this Agreement, this Section 9.1.3) is terminated
by Licensee for breach of the foregoing covenant by CAT, in which case such license will terminate
immediately and entirely.

     9.2 CAT Phage Display Improvements. Within [***] following conception or discovery by or on
behalf of CAT or its Affiliates of any CAT Phage Display Improvements, CAT will provide Licensee
with written notice of such CAT Phage Display Improvements (to the extent that such disclosure
would not violate CAT’s non-disclosure obligations to one or more Third Parties). If Licensee
elects to include any Patents claiming or covering one or more of such CAT Phage Display
Improvements, then Licensee will provide CAT with written notice of such election and, upon receipt
by CAT of such notice, any such Patents will be deemed CAT Licensed Patents hereunder. Subject to
the licenses granted in Section 2, CAT will retain all right, title and interest in and to any and
all CAT Phage Display Improvements.

     9.3 Further Assurances. Each Party agrees to take all necessary and proper acts, and will
cause its employees, Affiliates, contractors, sublicensees, and consultants to take such necessary
and proper acts, to effectuate the ownership provisions set forth in this Section 9.

10. Term And Termination

     10.1 Term. This Agreement is effective as of the Effective Date and will expire upon the last
date upon which the royalties payable by Licensee to CAT under Section 5.2.2 or 5.3.2 expire unless
terminated earlier as expressly provided otherwise in this Agreement (the “Term”).

     10.2 Termination for Material Breach.

          10.2.1 Any material breach or failure by a Party to comply with any of its obligations
contained herein (including, without limitation, any such breach or failure during an Insolvency
Event) will entitle the Party not in default to give to the Party in default written notice
specifying the nature of the default, requiring the defaulting Party to make good or otherwise cure
such default.

          10.2.2 Subject to Section 10.2.3 below, if, after a Party’s receipt of notice pursuant to
Section 10.2.1 above, such default is not cured within [***] days (or, if such default cannot be
cured within such [***]-day period, if the Party in default does not commence actions to cure such
default within such [***]-day period and thereafter diligently continue such actions and cure such
default within [***] days after the receipt of such notice, except in the case of a payment
default, as to which the defaulting Party will have only a [***]-day cure period), then the Party
not in default will be entitled, on written notice to the other Party and without prejudice to any
other rights conferred on it by this Agreement or available to it or them by law or in

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

20.

 

equity, to
terminate this Agreement immediately.

          10.2.3 If a Party receiving a notice pursuant to Section 10.2.1 above, is also at the time of
receiving such notice subject to an Insolvency Event and such default is not cured within [***]
days (except in the case of payment default, as to which the defaulting party will only have a
[***] day cure period), then the Party not in default will be entitled, on written notice to the
other Party and without prejudice to any other rights conferred by this Agreement or available to
it or them by law or in equity, to terminate this Agreement immediately.

     10.3 Amendment or Termination of [***] Agreement.

          10.3.1 Upon any amendment of the [***] Agreement that materially reduces the obligation of CAT
to pay royalties to [***] in connection with a sale of “Products” (as defined therein) by CAT or
its sublicensee (without a corresponding material payment by CAT of cash or in-kind consideration
therefor), then CAT will promptly notify Licensee of such amendment and the Parties will in good
faith promptly amend the applicable provisions of this Agreement in order to provide to Licensee,
as best as practicable, the economic benefits (or reduction of obligations) resulting from such
amendment to the [***] Agreement.

          10.3.2 Upon termination of the [***] Agreement, and upon request by Licensee, CAT will use
commercially reasonable efforts to obtain a direct license for Licensee from [***], its successors
or assigns to any CAT Licensed Patents licensed to CAT under such agreement upon the terms set
forth herein (including, without limitation, pursuant to Section [***] of the [***] Agreement);
provided, however, that CAT will have no such obligation if Licensee’s acts or
omissions under this Agreement caused such termination of the MRC Agreement.

     10.4 Consequences of Expiration and Termination.

          10.4.1 Material Breach. Upon termination of this Agreement by a Party pursuant to Section
10.2, (i) all licenses granted by the terminating Party to the defaulting Party will terminate
(except as provided in Section 9.1.3 and Section 10.4.2); (ii) the licenses granted by the
defaulting Party will survive (subject to continued performance by the terminating Party of its
royalty obligations, if any); and (iii) the milestone and royalty obligations set forth in Section
5 with respect to the surviving licenses will continue.

          10.4.2 Survival of Certain Sublicenses. Sublicenses granted by a defaulting Party to a Third
Party will survive termination of the defaulting Party’s license under Section
10.4.1(i); provided, however, that (x) such Third Party is not the cause of
the default, (y) such Third Party is not in breach of, and continues to fully perform all
obligations under its sublicense agreement and any surviving provisions in this Agreement
applicable to such sublicensee, and (z) the terminating Party continues to receive from such Third
Party all royalty and milestone payments set forth in Section 5.

          10.4.3 Return of Confidential Information. Upon any expiration or termination of this
Agreement, each Party will, at the other Party’s option, promptly return or

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

21.

 

destroy any of such
other Party’s Confidential Information (including all Know-How) in its possession or control;
provided, however, that each Party may retain: (a) a single archival copy of the
Confidential Information of the other Party solely for the availing itself of the rights accorded
to it, or to perform its obligations, under the surviving provisions of this Agreement (including,
without limitation any and all license or sublicense rights expressly made to survive termination
or expiration hereof); and (b) any portion of the Confidential Information of the other Party which
a Party is required by applicable law to retain.

     10.5 Survival. Expiration or termination of this Agreement for any reason will not relieve
the Parties of any obligation accruing prior to such expiration or termination, including without
limitation Licensee’s obligation to pay royalties under Section 5 above on the sale of Licensed
Products prior to the effective date of such expiration or termination. The provisions of Sections
3.1.2, 5 (solely as to accrued and unpaid amounts and Sections 5.5 and 5.7), 6.4, 7, 9.1.3, 10.4,
10.5, 11, 12 and 13, together with any definitions used or schedules referenced therein, will
survive termination or expiration of this Agreement.

11. Indemnification And Insurance

     11.1 Indemnification By Licensee. Licensee will indemnify CAT, its Affiliates, and their
respective directors, officers, employees and agents, and defend and save each of them harmless,
from and against any and all losses, damages, liabilities, costs and expenses (including reasonable
attorneys’ fees and expenses)(collectively, “Losses”) in connection with any and all liability
suits, investigations, claims or demands by Third Parties (each, a “Third Party Claim”) to the
extent arising out of: (a) any theory of product liability (including, but not limited to, actions
in the form of tort, warranty or strict liability) concerning a Licensed Product that is Exploited
by Licensee or its Affiliates pursuant to any right or license granted under this Agreement, or (b)
any failure by any sublicensee of Licensee to comply with the obligations of Sections 5.5, 7, 8.3
and 9.1 of this Agreement imposed on such sublicensee pursuant to Section 2.1 of this Agreement, as
applicable; in each case, except to the extent that such Losses arise out of or result from (i) the
gross negligence or reckless misconduct of a party seeking indemnification hereunder, or (ii) a
material breach by a party seeking indemnification hereunder of any provision of this Agreement.

     11.2 Indemnification Procedure.

          11.2.1 Notice of Claim. All indemnification claims in respect of a Party, its Affiliates or
their respective directors, officers, employees and agents (collectively, the “Indemnitees” and
each an “Indemnitee”) will be made solely by such Party to this Agreement (the “Indemnified
Party”). The Indemnified Party will give the indemnifying Party (the
“Indemnifying Party”) prompt written notice (an “Indemnification Claim Notice”) of any Losses
or discovery of fact upon which such Indemnified Party intends to base a request for
indemnification under this Section 11, but in no event will the Indemnifying Party be liable for
any Losses that result from any delay in providing such notice. Each Indemnification Claim Notice
must contain a description of the claim and the nature and amount of such Loss (to the extent that
the nature and amount of such Loss are known at such time). The Indemnified Party will furnish
promptly to the Indemnifying Party copies of all papers and official documents received in respect
of any Losses.

22.

 

          11.2.2 Prosecution of Claims. The obligations of an Indemnifying Party under this Section 11
will be governed by and be contingent upon the following additional terms and conditions:

               (a) Control of Defense.

                    (i) At its option, the Indemnifying Party may assume the defense of any Third Party Claim by
giving written notice to the Indemnified Party within thirty (30) days after the Indemnifying
Party’s receipt of an Indemnification Claim Notice.

                    (ii) Upon assuming the defense of a Third Party Claim, the Indemnifying Party may appoint as
lead counsel in the defense of the Third Party Claim any legal counsel selected by the Indemnifying
Party. In the event the Indemnifying Party assumes the defense of a Third Party Claim, the
Indemnified Party will immediately deliver to the Indemnifying Party all original notices and
documents (including court papers) received by any Indemnitee in connection with the Third Party
Claim. Should the Indemnifying Party assume the defense of a Third Party Claim, the Indemnifying
Party will not be liable to the Indemnified Party or any other Indemnitee for any legal expenses
subsequently incurred by such Indemnified Party or other Indemnitee in connection with the
analysis, defense or settlement of the Third Party Claim.

               (b) Right to Participate in Defense. Without limiting Section 11.2.2(a), any Indemnitee will
be entitled to participate in, but not control, the defense of such Third Party Claim and to employ
counsel of its choice for such purpose; provided, however, that such employment
will be at the Indemnitee’s own expense unless (i) the employment thereof has been specifically
authorized by the Indemnifying Party in writing, or (ii) the Indemnifying Party has failed to
assume the defense and employ counsel in accordance with Section 11.2.2(a) (in which case the
Indemnified Party will control the defense).

               (c) Settlement. With respect to any Losses relating solely to the payment of money damages in
connection with a Third Party Claim and that will not result in the Indemnitee’s becoming subject
to injunctive or other relief or otherwise adversely affect the business of the Indemnitee in any
manner, and as to which the Indemnifying Party will have acknowledged in writing the obligation to
indemnify the Indemnitee hereunder, the Indemnifying Party will have the sole right to consent to
the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such
terms as the Indemnifying Party, in its sole discretion, will deem appropriate, and will transfer
to the Indemnified Party all amounts which said Indemnified Party will be liable to pay prior to
the time prior to the entry of judgment. With
respect to all other Losses in connection with Third Party Claims, where the Indemnifying
Party has assumed the defense of the Third Party Claim in accordance with Section 11.2.2(a), the
Indemnifying Party will have authority to consent to the entry of any judgment, enter into any
settlement or otherwise dispose of such Loss provided it obtains the prior written consent of the
Indemnified Party (which consent will be at the Indemnified Party’s sole and absolute discretion).
The Indemnifying Party will not be liable for any settlement or other disposition of a Loss by an
Indemnitee that is reached without the written consent of the Indemnifying Party. Regardless of
whether the Indemnifying Party chooses to defend or prosecute any Third Party Claim, no Indemnitee
will admit any liability with respect to, or settle, compromise or discharge,

23.

 

any Third Party Claim
without the prior written consent of the Indemnifying Party.

               (d) Cooperation. Regardless of whether the Indemnifying Party chooses to defend or prosecute
any Third Party Claim, the Indemnified Party will, and will cause each other Indemnitee to,
cooperate in the defense or prosecution thereof and will furnish such records, information and
testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings,
trials and appeals as may be reasonably requested in connection therewith. Such cooperation will
include access during normal business hours afforded to the Indemnifying Party to, and reasonable
retention by the Indemnified Party of, records and information that are reasonably relevant to such
Third Party Claim, and making Indemnitees and other employees and agents available on a mutually
convenient basis to provide additional information and explanation of any material provided
hereunder, and the Indemnifying Party will reimburse the Indemnified Party for all its reasonable
out-of-pocket expenses in connection therewith.

     11.3 Expenses. Except as provided above, the reasonable and verifiable costs and expenses,
including fees and disbursements of counsel, incurred by the Indemnified Party in connection with
any claim will be reimbursed on a calendar quarter basis by the Indemnifying Party, without
prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to
indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to
be obligated to indemnify the Indemnified Party.

     11.4 Insurance. During the Term, each Party will have and maintain such types and amounts of
liability insurance as is normal and customary in the industry generally for parties similarly
situated, and will upon request provide the other Party with a copy of its policies of insurance in
that regard, along with any amendments and revisions thereto.

12. Limitation of Liability

     12.1 NOTHING IN THIS AGREEMENT WILL RESTRICT OR LIMIT EITHER PARTY’S LIABILITY FOR DEATH OR
PERSONAL INJURY CAUSED BY SUCH PARTY’S NEGLIGENCE OR WILLFUL MISCONDUCT.

     12.2 SUBJECT TO SECTION 12.1 ABOVE, IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY
FOR LOST PROFITS, LOSS OF DATA, OR FOR ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE
DAMAGES, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED
OF THE POSSIBILITY OF SUCH DAMAGES,
ARISING UNDER ANY CAUSE OF ACTION AND ARISING IN ANY WAY OUT OF THIS AGREEMENT. THE FOREGOING
LIMITATIONS WILL NOT APPLY TO DAMAGES ARISING FROM A BREACH OF SECTION 7 ABOVE OR AN AWARD OF
ENHANCED DAMAGES AVAILABLE UNDER THE PATENT LAWS FOR WILLFUL PATENT INFRINGEMENT, AND WILL NOT
LIMIT EITHER PARTY’S INDEMNITY OBLIGATIONS TO THE OTHER PARTY UNDER THIS AGREEMENT.

13. Miscellaneous

     13.1 Assignment. Without the prior written consent of the other Party (which such

24.

 

consent may
be granted, withheld or conditioned at the other Party’s sole and absolute discretion), neither
Party will sell, transfer, assign, delegate, pledge or otherwise dispose of, whether voluntarily,
involuntarily, by operation of law or otherwise, this Agreement or any of its rights or duties
hereunder; provided, however, that either Party may assign or transfer this
Agreement or any of its rights or obligations hereunder without the consent of the other Party:

               (a) to any Affiliate of such Party; provided, further, that

                    (i) such Affiliate may not otherwise sell, transfer, assign, delegate, pledge or otherwise
dispose of, whether voluntarily, involuntarily, by operation of law or otherwise (except pursuant
to any merger, consolidation or asset sale subject to Section 13.1(b) below), this Agreement or any
of its rights or duties hereunder without the prior written consent of the other Party and such
consent may be granted, withheld or conditioned at the other Party’s sole and absolute discretion;
and

                    (ii) that if any such Affiliate is subsequently sold by or otherwise ceases to be an Affiliate
of the relevant Party (except pursuant to any merger, consolidation or asset sale subject to
Section 13.1(b) below) this Agreement must be assigned back to the relevant Party before such sale
or other event becomes effective; or

               (b) to any Third Party with which it merges or consolidates, or to which it transfers all or
substantially all of its assets to which this Agreement relates.

In each case described in this Section 13.1 the relevant Affiliate assignee, Third Party assignee
or surviving entity will assume in writing all of the assigning Party’s obligations under this
Agreement and the assigning Party will promptly provide notice to the other Party of such
assignment. The assigning Party (except if it is not the surviving entity) will remain jointly and
severally liable under this Agreement with the relevant Affiliate assignee. Any purported
assignment or transfer in violation of this Section will be void ab initio and of no force or
effect.

     13.2 Severability. If any provision of this Agreement is held to be illegal, invalid or
unenforceable under any present or future law, then (a) such provision will be fully severable, (b)
this Agreement will be construed and enforced as if such illegal, invalid or unenforceable
provision had never comprised a part hereof, (c) the remaining provisions of this Agreement will
remain in full force and effect and will not be affected by the illegal, invalid or unenforceable
provision or by its severance from this Agreement, and (d) the Parties will use good faith efforts
to promptly replace such illegal, invalid or unenforceable provision with a valid and enforceable
provision having similar terms such that the objectives contemplated by
the Parties when entering this Agreement may be realized. To the fullest extent permitted by
applicable law, each Party hereby waives any provision of law that would render any provision
prohibited or unenforceable in any respect.

     13.3 Governing Law; Dispute Resolution.

          13.3.1 This Agreement, all disputes between the Parties related to or arising out of this
Agreement, the Parties’ relationship created hereby, and/or the negotiations for and entry into
this Agreement, including any dispute concerning its conclusion, binding effect, amendment,
coverage, or termination, will be governed by the laws of England and Wales

25.

 

without reference to
any choice of law principles that would cause the application of the laws of a different
jurisdiction, and will (subject to Section 13.3.2 below) be subject to the non-exclusive
jurisdiction of the courts of competent jurisdiction located in England and Germany.

          13.3.2 The Parties will try to settle their differences amicably between themselves. In the
event of any controversy or claim arising out of or relating to any provision of this Agreement or
the performance or alleged non-performance of a Party of its obligations under this Agreement
(“Dispute”), a Party may notify the other Party in writing of such Dispute. If the Parties are
unable to resolve the Dispute within [***] of receipt of the written notice by the other Party,
such dispute will be referred to [***] [***] who will use their good faith efforts to resolve the
Dispute within [***] after it was referred to [***]. If [***] fail to resolve the Dispute, each
Party may pursue its rights and remedies as described in Section 13.3.1 above. Notwithstanding the
foregoing, no Dispute relating to Section 7 will be subject to this Section 13.3.2. In addition,
nothing in this Section 13.3.2 will limit either Party’s right to seek immediate injunctive or
other equitable relief whenever the facts or circumstances would permit a Party to seek such relief
in a court of competent jurisdiction.

     13.4 Notices. All notices or other communications that are required or permitted hereunder
will be in writing and delivered personally, sent by facsimile (and promptly confirmed by personal
delivery or overnight courier as provided herein), or sent by internationally-recognized overnight
courier addressed as follows:

     If to CAT, to:

Cambridge Antibody Technology Ltd

Milstein Building, Granta Park

Cambridgeshire CB 1 6GH

England

Attention: the Company Secretary

Facsimile: +44 (0) 1223 471472

     If to Licensee, to:

Micromet AG

Staffelseestrasse 2

D-81477 Munich, Germany

Attention: Chief Business Officer

Facsimile: +49 89 895-277-285

with a copy to:

Cooley Godward LLP

One Freedom Square

Reston Town Center

11951 Freedom Drive

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

26.

 

Reston, Virginia 20190-5656

Attention: Matthias Alder, Esq.

Facsimile: +1 (703) 456-8100

or to such other address as the Party to whom notice is to be given may have furnished to the other
Party in writing in accordance herewith. Any such communication will be deemed to have been given
(i) when delivered, if personally delivered or sent by facsimile on a Business Day, and (ii) on the
second Business Day after dispatch, if sent by internationally-recognized overnight courier. It is
understood and agreed that this Section 13.4 is not intended to govern the day-to-day business
communications necessary between the Parties in performing their duties, in due course, under the
terms of this Agreement.

     13.5 Entire Agreement; Modifications. This Agreement, together with any schedules attached
hereto (each of which is hereby incorporated herein by reference), sets forth and constitutes the
entire agreement and understanding between the Parties with respect to the subject matter hereof
and all prior agreements, understanding, promises and representations, whether written or oral,
with respect thereto are hereby superceded and of no further force and effect. Each Party confirms
that it is not relying on any representations or warranties of the other Party except as
specifically set forth herein. For the avoidance of doubt, nothing in this Agreement is intended to
or shall be construed to provide that (a) a representation, covenant or obligation under this
Agreement shall be a representation, covenant or obligation under any other agreement or instrument
executed by the Parties, except as expressly provided otherwise herein, or (b) a default under this
Agreement shall constitute a default under any other agreement or instrument executed by the
Parties, except as expressly provided otherwise herein. No amendment or modification of this
Agreement will be binding upon the Parties unless made in writing and duly executed by authorized
representatives of both Parties.

     13.6 Relationship of the Parties. It is expressly agreed that the Parties’ relationship under
this Agreement is strictly one of licensor-licensee, and that this Agreement does not create or
constitute a partnership, joint venture, or agency. Neither Party will have the authority to make
any statements, representations or commitments of any kind, or to take any action, which will be
binding (or purport to be binding) on the other. All persons employed by a Party will be employees
of such Party and not of the other Party and all costs and obligations incurred by reason of any
such employment will be for the account and expense of such Party.

     13.7 Waiver. Any term or condition of this Agreement may be waived at any time by the Party
that is entitled to the benefit thereof, but no such waiver will be effective unless
set forth in a written instrument duly executed by or on behalf of the Party waiving such term
or condition. The waiver by either Party of any right hereunder or of claims based on the failure
to perform or a breach by the other Party will not be deemed a waiver of any other right hereunder
or of any other breach or failure by said other Party whether of a similar nature or otherwise.

     13.8 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of
which will be deemed an original, but all of which together will constitute one and the same
instrument.

     13.9 No Benefit to Third Parties. The representations, warranties, covenants and

27.

 

agreements
set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and
permitted assigns, and they will not be construed as conferring any rights on any other parties.

     13.10 Further Assurance. Each Party will duly execute and deliver, or cause to be duly
executed and delivered, such further instruments and do and cause to be done such further acts and
things, including the filing of such assignments, agreements, documents and instruments, as may be
necessary or as the other Party may reasonably request in connection with this Agreement or to
carry out more effectively the provisions and purposes, or to better assure and confirm unto such
other Party its rights and remedies under this Agreement.

     13.11 English Language. This Agreement has been written and executed in the English language.
Any translation into any other language will not be an official version thereof, and in the event
of any conflict in interpretation between the English version and such translation, the English
version will control.

     13.12 Force Majeure. Neither Party will be deemed to be in breach of this Agreement as a
result of default, delay or failure to perform by such Party that results from any cause beyond the
reasonable control of such Party that could not reasonably be foreseen by such Party, including
without limitation, fire, earthquake, acts of God, acts of war, strikes, lockouts, or other labor
disputes, riots, civil disturbances, actions or inactions of governmental authorities (except
actions in response to a breach of applicable laws by such Party), or epidemics. This Section 13.12
will not operate to excuse payment by a Party of any amounts due to any other Party under this
Agreement. In the event of any such force majeure, the Party affected will promptly notify the
other Party, will use commercially reasonable efforts to overcome such force majeure, and will keep
the other Party informed with respect thereto. If the event of force majeure continues for a period
greater than one hundred and eighty (180) days, then the unaffected Party may terminate this
Agreement immediately by notice in writing to the affected Party.

     13.13 Construction. Except where the context otherwise requires, wherever used, the singular
will include the plural, the plural the singular, the use of any gender will be applicable to all
genders and the word “or” is used in the inclusive sense (and/or). The captions of this Agreement
are for convenience of reference only and in no way define, describe, extend or limit the scope or
intent of this Agreement or the intent of any provision contained in this Agreement. The term
“including” as used herein means including, without limiting the generality of any description
preceding such term. No rule of strict construction will be applied against
either Party.

[Remainder of this page is left blank intentionally. Signature page follows.]

28.

 

     In Witness Whereof, the Parties have executed this Agreement by their respective
authorized representatives as of the date first written above.

	 	 	 	 	 
	Cambridge Antibody Technology Limited	 
	 
	 	 	 	 
	By:

	 	/s/ Diane Mellett	 	 
	Name:

	 	 

Diane Mellett
	 	 
	Title:

	 	General Counsel	 	 

	 	 	 	 	 
	Micromet AG	 	 
	 
	 	 	 	 
	By:

	 	/s/ Christian Itin	 	 
	Name:

	 	 

Christian Itin, Ph.D
	 	 
	Title:

	 	Chief Business Officer	 	 
	 
	 	 	 	 
	By:

	 	/s/ Gregor K. Mirow	 	 
	Name:

	 	 

Gregor K. Mirow
	 	 
	Title:

	 	CFO	 	 

[Signature Page To The Non-Exclusive Product License Agreement]

1

 

Schedule I

CAT Licensed Patents

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	[***]	 	 	 	[***]	[***]	[***]	[***]
	 	 	 	 	 	 	 	 	 	 	 
	PUBLISHED PCT

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	US

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	EUROPE

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	AUSTRALIA

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	JAPAN

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	CANADA

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	SOUTH KOREA

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	[***]

 

			
	*	 	Patents in opposition proceedings.
	 
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

1

 

Schedule II

CAT Background Know-How

[***]:[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

1

 

SCHEDULE III

Description of Target

Human GM-CSF

SWISS-PROT entry name CSF2_HUMAN; accession number: P04141

Amino acid sequence of unprocessed precursor of GM-CSF

[***]

Nucleotide Sequence of GM-CSF

	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	 	 	 	 	 	 	 	 	[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

1

 

Schedule IV

Excluded Field

“Excluded Field” means:

	1.	 	the discovery, isolation, characterization, research, development, and/or commercialization
of an Antibody useful for the diagnosis, treatment and/or prevention of one or more of the
following disease conditions wherein the primary scientific rationale or activity is [***];
	 
	2.	 	[***] including, without limitation, (A) [***]e, and (B) [***]but, in both instances,
excluding the treatment and/or prevention of [***]associated with [***]);
	 
	3.	 	[***];
	 
	4.	 	[***] including, but not limited to, (A) [***](B) [***] and (C) [***];
	 
	5.	 	[***];
	 
	6.	 	[***]; and/or
	 
	7.	 	[***];

provided, however, that for the purpose of this Agreement the term “Excluded Field”
will not include the diagnosis, treatment and/or prevention of the above disease conditions caused
by [***].

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

1

 

Schedule V

Excluded Technologies

“Excluded Technology” means:

	1.	 	“[***],” meaning the technology claimed in the following Patents to which CAT has sole right,
title and interest: [***];
	 
	2.	 	“[***],” meaning solely Antibodies which [***] and in which [***];
	 
	3.	 	“Research Products,” meaning those certain research products for which CAT has granted
certain exclusive rights to a Third Party under the [***] License Agreement, as may then be in
effect;
	 
	4.	 	“[***],” meaning any Antibody [***] for the purpose of simultaneously detecting and/or
measuring [***] whereby that product:

	 	(a)	 	Contains or comprises:

	 	(i)	 	an [***] of [***] Antibodies of different [***]
[***] (excluding Antibodies serving a purpose as controls), or
	 
	 	(ii)	 	an [***] of [***] Antibodies of the same [***]
[***], provided that such Antibody is used to [***] [***] [***] data
points for the purpose of [***] (excluding Antibodies serving a purpose
as controls), and

	 	(b)	 	contains or comprises an array of Antibodies [***], and
	 
	 	(c)	 	is in a format where the [***], and
	 
	 	(d)	 	employs any type of [***], and
	 
	 	(e)	 	may be used [***] or [***] (as appropriate), and
	 
	 	(f)	 	is not, by way of example, (i) any type of [***] technology; (ii) any type of
[***] technology; (iii) any type of [***] assay.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

1

 

Schedule VI

CAT Third Party Claims

[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

1

 

Table of Contents

	 	 	 	 	 
	 	 	Page
	1. DEFINITIONS
	 	 	1	 
	2. GRANT OF LICENSES
	 	 	7	 
	2.1 License
	 	 	7	 
	2.2 Reservation of Rights
	 	 	7	 
	2.3 Excluded Technology
	 	 	7	 
	2.4 Know-How Transfer
	 	 	8	 
	3. IDENTIFICATION OF LICENSED PRODUCTS; REPORTING; DILIGENCE
	 	 	8	 
	3.1 Identification of Licensed Products
	 	 	8	 
	3.2 Abandonment of a Licensed Product
	 	 	8	 
	3.3 Dossier Updates
	 	 	8	 
	4. GATEKEEPING AND THE EXCLUDED FIELD
	 	 	9	 
	5. PAYMENTS
	 	 	9	 
	5.1 Initial License Fee
	 	 	9	 
	5.2 Therapeutic Licensed Product Milestone Payments and Royalty Rates
	 	 	9	 
	5.3 Diagnostic Licensed Product Milestone Payments and Royalty Rates
	 	 	10	 
	5.4 Payment
	 	 	11	 
	5.5 Records; Audits
	 	 	12	 
	5.6 Payment of Additional Amounts
	 	 	13	 
	5.7 Confidentiality
	 	 	13	 
	5.8 Withholdings
	 	 	13	 
	6. REPRESENTATION AND WARRANTIES; COVENANTS
	 	 	14	 
	6.1 Representations of CAT
	 	 	14	 
	6.2 Reciprocal Representations and Warranties
	 	 	14	 
	6.3 Additional Covenants
	 	 	14	 
	6.4 DISCLAIMER OF WARRANTY
	 	 	15	 
	7. CONFIDENTIALITY
	 	 	15	 
	7.1 Definition
	 	 	15	 
	7.2 Exclusions
	 	 	15	 
	7.3 Disclosure and Use Restriction
	 	 	16	 
	7.4 Authorized Disclosure
	 	 	16	 

-i-

 

Table
of
Contents
(continued)

	 	 	 	 	 
	 	 	Page
	7.5 Use of Name
	 	 	17	 
	7.6 Terms of Agreement to be Maintained in Confidence
	 	 	17	 
	7.7 Press Release
	 	 	17	 
	8. FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS
	 	 	17	 
	8.1 Prosecution and Maintenance
	 	 	17	 
	8.2 Costs
	 	 	18	 
	8.3 No Challenge
	 	 	18	 
	8.4 Notice
	 	 	18	 
	8.5 Enforcement
	 	 	18	 
	9. IMPROVEMENTS; OWNERSHIP
	 	 	18	 
	9.1 Phage Display Improvements
	 	 	18	 
	9.2 CAT Phage Display Improvements
	 	 	19	 
	9.3 Further Assurances
	 	 	19	 
	10. TERM AND TERMINATION
	 	 	19	 
	10.1 Term
	 	 	19	 
	10.2 Termination for Material Breach
	 	 	19	 
	10.3 Amendment or Termination of [***] Agreement
	 	 	20	 
	10.4 Consequences of Expiration and Termination
	 	 	20	 
	10.5 Survival
	 	 	21	 
	11. INDEMNIFICATION AND INSURANCE
	 	 	21	 
	11.1 Indemnification By Licensee
	 	 	21	 
	11.2 Indemnification Procedure
	 	 	22	 
	11.3 Expenses
	 	 	23	 
	11.4 Insurance
	 	 	23	 
	12. LIMITATION OF LIABILITY
	 	 	23	 
	13. MISCELLANEOUS
	 	 	24	 
	13.1 Assignment
	 	 	24	 
	13.2 Severability
	 	 	24	 
	13.3 Governing Law; Dispute Resolution
	 	 	25	 
	13.4 Notices
	 	 	25	 

 

			
	***	 	Certain information on this page has been omitted.

-ii-

 

Table
of
Contents
(continued)

	 	 	 	 	 
	 	 	Page
	13.5 Entire Agreement; Modifications
	 	 	26	 
	13.6 Relationship of the Parties
	 	 	26	 
	13.7 Waiver
	 	 	27	 
	13.8 Counterparts
	 	 	27	 
	13.9 No Benefit to Third Parties
	 	 	27	 
	13.10 Further Assurance
	 	 	27	 
	13.11 English Language
	 	 	27	 
	13.12 Force Majeure
	 	 	27	 
	13.13 Construction
	 	 	27	 

-iii-

 

Exhibit 10.38

***Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

Amendment

To

Non-Exclusive Product License Agreement

     This Amendment (the “Amendment”) is made as of this 17th day of March, 2005 by and
between Micromet AG, located at Staffelseestrasse 2, D-81477, Munich, Germany (“Micromet”)
and Cambridge Antibody Technology Limited, located at The Milstein Building, Granta Park,
Cambridgeshire CB 1 6GH, England (“CAT”)(each of Micromet, and CAT, a “Party” and, collectively,
the “Parties”).

Recitals

     A. The Parties have entered into that certain Non-Exclusive Product License Agreement, dated
as of November 3, 2003 (the “Agreement”), pursuant to which the Parties have granted certain
intellectual property licenses for products towards the GM-CSF target and for the purposes
described therein. Capitalized terms used herein without definition shall have the meanings given
to such terms in the Agreement.

     B. The Parties desire to amend the Agreement to delete the Excluded Field.

Agreement

     Now, Therefore, for and in consideration of the mutual promises and covenants set
forth herein and for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the Parties hereby agree as follows:

     1. Expiration of Excluded Field. The Parties acknowledge and agree that, effective as of 22
February, 2004, CAT has ceased to be bound by the Excluded Field restriction pursuant to its
agreement with [***] dated [***] and, consequently, pursuant to the terms of Section 2.3 of the
Agreement, any restrictions set forth in the Agreement relating to the Excluded Field have ceased
to apply as of 22 February 2004.

     2. Counterparts. This Amendment may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same
instrument.

     3. Effectiveness. This Amendment shall become effective upon the execution hereof by both
Parties.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

1.

 

     4. Continuing Effect. Other than as set forth in this Amendment, all of the terms and
conditions of the Agreement shall continue in full force and effect.

2.

 

     In Witness Whereof, the parties have executed this Amendment to the Non-Exclusive
Product License Agreement as of the date first written above.

	 	 	 	 	 	 	 
	Micromet AG	 	Cambridge Antibody Technology Limited
	 
	 	 	 	 	 	 
	By:

	 	/s/ Christian Itin
	 	By:
	 	/s/ Alasdair Moodie
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Name: Christian Itin	 	Name: Alasdair Moodie
	 
	 	 	 	 	 	 
	Title: CEO	 	Title: Assistant General Counsel

3.exv10w39

 

Exhibit 10.39

***Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

Amended and Restated Cross-License Agreement

     This Amended and Restated Cross-License Agreement (the “Agreement”) is entered into as of
June 28, 2004 (the “Amendment Date”) and is hereby made effective as of April 9, 2002 (the
“Effective Date”), by and between Micromet AG, having its principal offices at
Staffelseestrasse 2, 81477 Munich, Germany (“Micromet”), and Enzon Pharmaceuticals, Inc.,
having its principal offices at 685 Route 202/206, Bridgewater, New Jersey 08807, USA (“Enzon”).
Micromet and Enzon each may be referred to herein individually as a “Party,” or collectively as the
“Parties.”

     Whereas, the Parties have entered into that certain Cross-License Agreement, dated as
of April 9, 2002 (the “Original License Agreement”), pursuant to which the Parties granted each
other certain nonexclusive licenses with respect to certain patents owned by the Parties;

     Whereas, the Parties desire to amend and restate the Original License Agreement to
reflect certain amendments agreed upon in connection with the amendment and restatement of that
certain Amended and Restated Collaboration Agreement between Micromet and Enzon dated as of the
Effective Date (the “Collaboration Agreement”);

     Now, therefore, in consideration of the foregoing premises and the mutual promises
and covenants contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby
agree as follows:

1. Definitions

     When used in this Agreement, capitalized terms will have the meanings as defined below and
throughout the Agreement. Unless the context indicates otherwise, the singular will include the
plural and the plural will include the singular.

     1.1 “Affiliate” means a legal entity that, directly or indirectly, through one or more
intermediaries, controls, is controlled by, or is under common control with a Party. For purposes
of this definition only, “control” and, with correlative meanings, the terms “controlled by” and
“under common control with” means (a) the possession, directly or indirectly, of the power to
direct the management or policies of a legal entity, whether through the ownership of voting
securities or by contract relating to voting rights or corporate governance, or (b) the ownership,
directly or indirectly, of more than 50% of the voting securities or other ownership interest of a
legal entity; provided that, if local law restricts foreign ownership, control will be established
by direct or indirect ownership of the maximum ownership percentage that may, under such local law,
be owned by foreign interests

     1.2 “Antigen” means any structure with binding affinity to antibody variable domains.

 

 

     1.3 “BiTE Product” means any composition or formulation consisting of, containing or
comprising a bi-specific Single Chain Antibody expressed as a single polypeptide chain, binding to
T-cells for the diagnosis, prophylaxis or treatment of human or non-human diseases or conditions,
but excluding any BiTE Research Product.

     1.4 “BiTE Research Product” means any composition or formulation consisting of, containing or
comprising a bi-specific Single Chain Antibody expressed as a single polypeptide chain binding to
T-cells used for research purposes and not for the diagnosis, prophylaxis or treatment of human or
non-human diseases or conditions.

     1.5 “BLA” means a Biologics License Application, as defined in the U.S. Federal Food, Drug,
and Cosmetics Act, as amended, and the regulations promulgated thereunder, or a foreign equivalent
to such application.

     1.6 “Commencement” with respect to a clinical trial means the administration of the first dose
to a patient in the clinical trial.

     1.7 “Commercialization Rights” means the right or option (whether or not ultimately exercised)
to market, co-market, promote, co-promote or sell a product.

     1.8 “Consolidated Patent Portfolio” means the combined intellectual property portfolio
consisting of the Enzon Licensed Patents and the Micromet Licensed Patents.

     1.9 “Control” or “Controlled” means, with respect to any know-how, Patent, or other
intellectual property right, possession of the right, whether directly or indirectly, and whether
by ownership, license or otherwise, to assign, or grant a license, sublicense or other right to or
under, such know-how, Patent or right as provided for herein without violating the terms of any
agreement or other arrangements with any Third Party.

     1.10 “Curis Cross-License Agreements” means those certain cross-license agreements dated as of
November 23, 1993, between Enzon and Creative BioMolecules, Inc., with respect to which Curis, Inc.
was the assignee of Creative BioMolecules, Inc., and with respect to which Micromet was the
assignee of Curis, Inc.

     1.11 “Diagnostic SCA Product” means an SCA Product that is under development, approved or used
for the diagnosis of human diseases or conditions.

     1.12 “Enzon License” has the meaning assigned to it in section 2.2.1.

     1.13 “Enzon Licensed Patents” means those Patents now owned by or licensed to Enzon which were
the subject of a nonexclusive license to Micromet, as ultimate assignee of Creative BioMolecules,
Inc., pursuant to the Curis Cross-License Agreements, including without limitation those Patents
identified in Appendix A hereto, but excluding any Collaboration Patents (as defined in the
Collaboration Agreement).

     1.14 “Enzon Pipeline Product” means any Licensed Product, other than a BiTE Product or BiTE
Research Product, as to which (a) Enzon obtains or retains Commercialization

2

 

Rights (whether exclusive or co-exclusive) in one or more Major Market Countries, or (b) Enzon
or any of its Affiliates has filed or will file an IND in its own name.

     1.15 “Exploit” or “Exploitation” means to make, have made, import, use, sell, offer for sale,
or otherwise dispose of a product, including all discovery, research, development, registration,
modification, enhancement, improvement, manufacture, storage, formulation, exportation,
transportation, distribution, promotion and marketing activities related thereto.

     1.16 “First Phase III Trial” means the first controlled, randomized human clinical trial the
results of which could be or are used to establish the safety and efficacy of a pharmaceutical
product as a basis for a BLA, or that would otherwise satisfy the requirements of 21 CFR 312.21(c).

     1.17 “IL-2 Agreement” means that certain IL-2 License Agreement between the Parties, dated as
of the Amendment Date, relating to the transfer of certain rights and obligations with respect to
products binding to IL-2.

     1.18 “IND” means an investigational new drug application filed with the United States Food and
Drug Administration or its foreign equivalent, in each case for authorization to commence human
clinical trials.

     1.19 “Industrial SCA Product” means any composition or formulation consisting of, containing
or comprising one or more Single Chain Antibodies intended for any use other than for research or
the diagnosis, prophylaxis, or treatment of disease or conditions in humans and other animals.

     1.20 “Licensed Product” means any SCA Product, Non-Human SCA Product, Research Product,
Industrial SCA Product, BiTE Product, or BiTE Research Product, the composition, manufacture, use
of which is claimed by one or more Valid Claims of the Consolidated Patent Portfolio.

     1.21 “Micromet License” has the meaning assigned to it in section 2.1.1.

     1.22 “Major Market Country” means the [***].

     1.23 “Micromet Licensed Patents” means those Patents now owned by or licensed to Micromet
which were the subject of a nonexclusive sublicense to Enzon pursuant to the Curis Cross-License
Agreements, including without limitation those Patents identified in Appendix B hereto, but
excluding any Collaboration Patents (as defined in the Collaboration Agreement).

     1.24 “Micromet Pipeline Product” means any Licensed Product as to which (a) Micromet obtains
or retains Commercialization Rights (whether exclusive or co-exclusive) in one or more Major Market
Countries, or (b) Micromet or its Affiliates has filed or will file an IND in its own name.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

3

 

     1.25 “Net Sales” means all consideration received by a Party, an Affiliate, or a sublicensee
for the sale or other transfer or disposition of Licensed Products, less returns and customary
trade discounts actually taken, outbound freight, value added, sales or use taxes, tariffs, and
custom duties. For the avoidance of doubt, the above definition of Net Sales includes sales made
by a sublicensee as if such sales were made directly by a Party. In the case of transfers of
products to an Affiliate or sublicensee by a Party for sale or other disposition of such products
to Third Parties by such Affiliate or sublicensee, Net Sales will be the greater of the total fees
and other consideration charged by the Affiliate or sublicensee to Third Parties or the total fees
and consideration charged by the Party to the Affiliate or sublicensee, but not both amounts, and
no unit of any product will be subject to more than one sale or disposition that qualifies as a Net
Sale, regardless of the number or form of sales or dispositions of such unit.

     1.26 “Non-Human SCA Product” means any composition or formulation consisting of, containing or
comprising one or more Single Chain Antibodies under development, approved or used for the
diagnosis, prophylaxis or treatment of non-human diseases or conditions, but excluding any BiTE
Products.

     1.27 “Patents” means (a) all patents and patent applications in any country or supranational
jurisdiction, and (b) any substitutions, divisions, continuations, continuations-in-part, reissues,
renewals, registrations, confirmations, re-examinations, extensions, supplementary protection
certificates and the like, and any provisional applications, of any such patents or patent
applications.

     1.28 “Pegylated TNF-alpha Agreement” means that certain PEG TNF-alpha License Agreement
between the Parties, dated as of the Amendment Date, relating to the transfer of certain rights and
obligations with respect to a Pegylated Single Chain Antibody binding to TNF-alpha developed under
the Collaboration Agreement.

     1.29 “Research Product” means a product consisting of, containing or comprising one or more
Single Chain Antibodies used for research purposes and not intended, under development or used for
the diagnosis, prophylaxis or treatment of human or non-human diseases or conditions, but excluding
any BiTE Research Product.

     1.30 “SCA Product” means any composition or formulation consisting of, containing or
comprising one or more Single Chain Antibodies that is under development, approved or used for the
diagnosis, prophylaxis or treatment of human diseases or conditions, but excluding any BiTE
Product.

     1.31 “Single Chain Antibody” means a single chain polypeptide having binding affinity for an
antigen and a defined amino acid sequence whereby such polypeptide comprises (i) a first
polypeptide segment having a light chain variable region, (ii) a second polypeptide having a heavy
chain variable region, and (iii) at least one peptide linker linking the first and second
polypeptides into a single chain polypeptide.

     1.32 “Term” has the meaning assigned to it in section 7.1.

     1.33 “Therapeutic SCA Product” means an SCA Product under development or approved for the
treatment or prophylaxis of human diseases or conditions.

4

 

     1.34 “Third Party” means any party other than Micromet, Enzon or their respective Affiliates.

     1.35 “Third Party Collaboration Agreement” means any agreement executed during the Term
between a Party and a Third Party under which (a) such Party grants to such Third Party a license
to intellectual property or other rights Controlled by such Party (other than or in addition to any
Patent within the Collaboration Patents or the Consolidated Patent Portfolio) which intellectual
property or other rights are required for the performance of the research and development
activities to be performed under the agreement or for the Exploitation of products resulting from
such activities; and (b) each party to such agreement performs substantial research or development
activities pursuant to such agreement.

     By way of example but not limitation, such an agreement will qualify as a “Third Party
Collaboration Agreement” if the terms include (1) dedicated research funding paid by the Third
Party to the Party, or from the Party to the Third Party, of at least US$[***] over a period of
[***] following the execution of such agreement for the conduct of research pursuant to such
agreement, or (2) the performance of a project plan over a period of not less than [***] with
aggregate project costs for research activities of not less than US$[***] of which not less than
US$[***] are incurred by the Party (regardless of whether or not such costs are reimbursed by the
Third Party), or (3) governance provisions that provide [***] regarding the research activities to
be performed by the parties prior to the filing of an IND. For the avoidance of doubt, “Third
Party Collaboration Agreement” does not include any fee-for-service arrangement, or arrangement
wherein the extent of a Party’s collaboration is so limited that the grant of rights is in effect a
naked license grant.

     1.36 “Third Party Collaboration Product” means a product that is developed under and pursuant
to a Third Party Collaboration Agreement.

     1.37 “Valid Claim” means (a) any claim of an issued and unexpired patent within the Enzon
Licensed Patents or the Micromet Licensed Patents which has not been held unenforceable or invalid
by a court or other governmental agency of competent jurisdiction in an unappealed or unappealable
decision, and which has not been disclaimed or admitted to be invalid or unenforceable through
reissue or otherwise, or (b) a pending claim in a pending patent application within the Enzon
Licensed Patents or the Micromet Licensed Patents. Notwithstanding clause (b) above, in the event
that a pending claim in a pending patent application does not issue as a valid and enforceable
claim in an issued patent within [***] years after the earliest date from which such patent
application claims priority, such a pending claim will not be a Valid Claim, unless and until such
pending claim subsequently issues as a valid and enforceable claim in an issued patent, in which
case such claim will be reinstated and be deemed to be a Valid Claim as of the date of issuance of
such patent.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

5

 

2. Grant Of License

     2.1 License Grant By Micromet.

          2.1.1 Micromet hereby grants to Enzon a non-exclusive, worldwide, royalty-bearing (as provided
in section 3) license under the Micromet Licensed Patents to Exploit Licensed Products other than
BiTE Products (the “Micromet License”), provided, however, that the Exploitation of
BiTE Research Products will be limited to research activities that do not include administration to
humans of a BiTE Research Product. Under no circumstances will Enzon engage in any commercial
exploitation of BiTE Research Products (including, without limitation, any sale of such products
and any development activities aimed at creating BiTE Research Products for commercial sale). The
Micromet License shall be subject to the field limitations set forth on Appendix C.

          2.1.2 Enzon may grant and authorize the grant of sublicenses under the Micromet License and
may grant licenses under the Enzon Licensed Patents only for Enzon Pipeline Products and Third
Party Collaboration Products.

     2.2 License Grant By Enzon.

          2.2.1 Enzon hereby grants to Micromet a non-exclusive, worldwide, royalty-bearing (as provided
in section 3) license, under the Enzon Licensed Patents to Exploit Licensed Products other than
BiTE Products and BiTE Research Products (the “Enzon License”). The Enzon License shall be subject
to the field limitations set forth on Appendix C.

          2.2.2 Except as otherwise permitted in that certain Exclusive IP Marketing Agreement between
Micromet and Enzon dated as of the Effective Date (the “Marketing Agreement”), Micromet may grant
and authorize the grant of sublicenses under the Enzon License only for Micromet Pipeline Products
and Third Party Collaboration Products.

          2.2.3 Enzon hereby grants to Micromet an exclusive (even as to Enzon), worldwide, fully-paid,
royalty-free, perpetual, irrevocable, non-terminable, license, with the right to grant and
authorize the grant of sublicenses, under the Enzon Licensed Patents to Exploit any BiTE Products
and BiTE Research Products (subject to Enzon’s right to Exploit BiTE Research Products in
connection with research activities that do not include administration to humans of a BiTE Research
Product); provided, that under no circumstances will Enzon engage in any commercial
exploitation of BiTE Research Products (including, without limitation, any sale of such products
and any development activities aimed at creating BiTE Research Products for commercial sale).

     2.3 Amending Field Limitations. The field limitations listed in Appendix C set forth the
understanding of the Parties as of the Effective Date regarding the scope of such limitations
arising from license agreements under which licenses to Patents within the Consolidated Patent
Portfolio were granted to Third Parties prior to the Effective Date. Upon request of a Party, the
Parties will amend Appendix C as necessary to include additional or different limitations of which
the requesting Party in good faith was unaware as of the Effective Date. Furthermore, upon
expiration or termination of a license agreement that was the basis of a

6

 

limitation listed in Appendix C, such limitation will be deemed stricken from Appendix C as of
the date of such expiration or termination.

3. Milestones and Royalties

     3.1 Milestone Payments and Royalty Rates.

          3.1.1 Milestones.

               (a) Each Party will pay to the other Party the following milestone payments for each
Therapeutic SCA Product that is a Licensed Product Exploited by it, an Affiliate, or sublicensee:

     Milestones:

	 	 	 	 	 
	Upon acceptance of the first IND
	 	US$[***]
	Upon Commencement of First Phase III Trial*
	 	US$[***]
	Upon the first BLA approval in the United States
	 	US$[***]

 

			
	*	 	If this milestone has not been paid before the first filing of the BLA, it will be paid on the
date of such filing.

               (b) Each Party will pay to the other Party the following milestone payments for (i) each
Diagnostic SCA Product that is a Licensed Product, and (ii) each Non-Human SCA Product that is a
Licensed Product, in each case that is Exploited by it, an Affiliate, or sublicense:

Milestones:

	 	 	 	 	 
	Upon the first commercial sale
	 	US$[***]
	Upon cumulative sales reaching US$[***]
	 	US$[***]

          3.1.2 Royalties. Except as provided below and in section 3.1.3, each Party will pay to the
other Party the following royalties on Net Sales of each Licensed Product Exploited by it, an
Affiliate, or sublicensee:

     Royalties on annual worldwide Net Sales at the following incremental levels:

	 	 	 	 	 
	On Net Sales of each Licensed Product below US$[***]:
	 	 	[***]	%
	On Net Sales of each Licensed Product between US$[***]and US$[***]:
	 	 	[***]	%
	On Net Sales of each Licensed Product over US$[***]:
	 	 	[***]	%

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

7

 

     The royalty payment obligations of Micromet and Enzon under this section 3.1.2: (a) arise
without regard to the identity of the applicable Patents within the Consolidated Patent Portfolio
(i.e., Enzon will pay royalties to Micromet even if the only applicable Patents are Enzon Licensed
Patents, and Micromet will pay royalties to Enzon even if the only applicable Patents are Micromet
Licensed Patents), and (b) will expire on a product-by-product and country-by-country basis upon
the expiration of the last to expire Valid Claim embracing such product (or the manufacture or use
thereof) in a particular country. For the avoidance of doubt, the royalty payment obligations of
Micromet and Enzon under this section 3.1.2 arise only for Licensed Products that are made, used,
or sold in countries wherein such activities are embraced by one or more Valid Claims within the
Consolidated Patent Portfolio (each such country a “Royalty Country”), and the determination of the
Net Sales level and the applicable royalty rate with respect to a particular Licensed Product are
made based on the total Net Sales of such Licensed Product generated in all Royalty Countries in a
particular calendar year.

          3.1.3 Notwithstanding anything in this Agreement to the contrary, Micromet has no obligation
to pay any royalties to Enzon with respect to BiTE Products Exploited by Micromet, its Affiliates
or sublicensees under this Agreement, and neither Party has an obligation to pay any royalties to
the other Party with respect to BiTE Research Products Exploited by it, its Affiliates or
sublicensees under this Agreement.

          3.1.4 No milestone or royalty payments will be due under this Agreement for Licensed Products
jointly Exploited by both Parties under the terms of the Collaboration Agreement or any Product
Development and Commercialization Agreement (as defined in the Collaboration Agreement) executed
thereunder and the financial terms of such other agreements will govern with respect to products
Exploited under such other agreements. In addition no royalties or milestone payments will be due
under this Agreement with respect to the Exploitation of Licensed Products by Micromet under the
terms of the IL-2 Agreement or by Enzon under the terms of the Pegylated TNF-alpha Agreement.

          3.1.5 If Micromet grants a Consolidated Patent License (as defined in the Marketing Agreement)
for Third Party SCA Products (as defined in the Marketing Agreement) Exploited for the treatment or
prophylaxis of human diseases or conditions that does not provide for at least either (a) an
upfront license fee of at least US$[***] in cash or cash equivalents payable upon execution of same,
or (b) license fees and milestone payments totaling at least US$[***]in cash or cash
equivalents and a royalty equal to at least [***]% of the [***], then the milestones and
royalties that Enzon is obligated to pay to Micromet under sections 3.1.1(a) and 3.1.2 above will
be reduced (effective as of the grant of such Consolidated Patent License) at Enzon’s option to the
extent necessary to equal those of such Consolidated Patent License.

     3.2 Payment.

          3.2.1 Payment of Milestones. The Party achieving a development milestone that triggers a
milestone payment obligation pursuant to section 3.1 will give notice to the other

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

8

 

Party within [***] of achieving each milestone, and will make the corresponding milestone
payment within [***] of the achievement of the corresponding milestone event.

          3.2.2 Payment of Royalties. A Party who is obligated to make royalty payments pursuant to
section 3.1 will provide to the other Party within [***] after the end of each calendar quarter a
written report with such Party’s good faith estimate of Net Sales accrued in the preceding calendar
quarter and the royalties payable thereon. Such Party will make royalty payments to the other
Party for products sold during a calendar quarter within [***] of the last day of that calendar
quarter. Each royalty payment will be accompanied by a written report for that calendar quarter
showing the cumulative Net Sales of the applicable product sold by such Party, its Affiliates and
its sublicensees on a country-by-country basis worldwide during the quarterly reporting period and
the corresponding royalties payable under this Agreement.

          3.2.3 Payment Method. All amounts due hereunder will be paid in US Dollars by wire transfer
in immediately available funds to an account designated by the receiving Party. Any payments or
portions thereof due hereunder which are not paid on the date such payments are due will bear
interest from the due date until the date of payment at the rate which is the lower of (i) [***]%
over the overnight London Interbank Offering Rate in effect on the due date or (ii) the highest
rate permitted by applicable law, calculated on the number of days such payment is delinquent,
compounded monthly.

          3.2.4 Currency Conversion for Milestone Payments and Calculation of Net Sales. For any
currency conversion required in connection with any payment hereunder, or in determining the amount
of royalties due, such conversion will be made at the prevailing commercial rate of exchange for
purchasing the currency into which an amount is to be converted as publicly announced by Citibank
N.A. (or its successor) in New York on the last business day of the calendar quarter to which such
payments relate. The Net Sales used for computing the royalties will be computed in US Dollars.
For purposes of determining the amount of royalties due, the amount of Net Sales in any foreign
currency will be computed by converting such amount into US Dollars as provided in this section
above.

          3.2.5 Records Retention. Each Party will maintain complete and accurate books, records and
accounts in sufficient detail to confirm the accuracy of any payments required hereunder, which
books, records and accounts will be retained by such Party until [***] years after the end of the
period to which such books, records and accounts pertain.

          3.2.6 Audit. Each Party will have the right to have an independent certified public
accounting firm of internationally recognized standing, reasonably acceptable to the audited Party,
to have access during normal business hours, and upon reasonable prior written notice, to such of
the records of the other Party as may be reasonably necessary to verify the accuracy of information
needed to calculate payments required hereunder (“Payment Information”) for any calendar quarter
ending not more than [***] months prior to the date of such request; provided,
however, that the auditing Party will not have the right to conduct more than [***]. The
accounting firm will disclose to both Parties whether such Payment Information

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

9

 

is correct or incorrect and the specific details concerning any discrepancies. The auditing
Party will bear all costs of such audit, unless the audit reveals an underpayment of more than
[***]% from the amount paid, in which case the other Party will bear the cost of the audit.

          3.2.7 Payment of Additional Amounts. If, based on the results of any audit, additional
payments are owed by a Party under this Agreement, such Party will make such additional payments
promptly after the accounting firm’s written report is delivered to both Parties. If, based on the
results of any audit, payments made pursuant to section 3.1 exceeded payments indicated by the
audit as being due thereunder, such excess will be credited against future amounts owed by the
applicable Party under section 3.1.

          3.2.8 Confidentiality. Each Party will treat all information subject to review under this
section 3.2 in accordance with the confidentiality provisions of section 6 and will cause its
accounting firm to enter into a reasonably acceptable confidentiality agreement with the audited
Party obligating such firm to maintain all such financial information in confidence pursuant to
such confidentiality agreement.

4. Filing, Prosecution and Maintenance of Patent Rights

     4.1 Each Party will be solely responsible and bear all costs for the preparation, filing,
prosecution and maintenance of its licensed Patents in its sole and absolute discretion.

     4.2 If either Party elects not to continue prosecution or maintenance of any of its licensed
Patents, such Party will so notify the other Party at least [***] days prior to the final due date
of a response to any official action or on which a maintenance fee is due or other action is
required to maintain such Patent in force or continue prosecution of such Patent (in the case of a
patent application). The other Party (the “Continuing Party”) may elect to continue prosecution or
maintenance of such Patent, at its sole expense, in which event the non-Continuing Party will
assign such Patent to the Continuing Party and such Patent will be deemed a licensed Patent of the
Continuing Party, i.e., one of the Enzon Licensed Patents if Enzon is the Continuing Party and one
of the Micromet Licensed Patents if Micromet is the Continuing Party.

     4.3 Each Party will be solely responsible and bear all costs for (and enjoy all recovery from)
any inter partes actions concerning its licensed Patents, including but not limited to
reexaminations, oppositions, interferences, and infringement actions, all in its sole and absolute
discretion.

     4.4 Each Party will (i) promptly notify the other of any actions that may arise pursuant to
section 4.3 and (ii) provide the other on an annual basis a report on the status of its activities
described in section 4.1.

5. Representation and Warranties

     5.1 Reciprocal Representations and Warranties. Each Party represents and warrants to the other
Party that: (i) it has the right to grant the licenses granted by it pursuant to

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

10

 

this Agreement; and (ii) the licenses so granted do not conflict with or violate the terms of
any agreement, assignment, or encumbrance between such Party and any person or company.

     5.2 Curis. Micromet represents and warrants as of the Amendment Date that (i) Micromet has
fully and faithfully performed all obligations under that certain Agreement for Purchase and Sale
of Single-Chain Polypeptide Business dated as of June 29, 2001, between Micromet and Curis, Inc.
(hereafter, the “Curis Transfer Agreement”), (ii) the Curis Transfer Agreement is in full force and
effect, (iii) there have been no events of breach by Micromet of the Curis Transfer Agreement which
would materially affect in an adverse manner Enzon’s rights under this Agreement, and (iv) Micromet
has not received from Curis any notification, written or oral, that Micromet has been, is, or may
be in breach of the Curis Transfer Agreement. Micromet will take all action necessary to maintain
the Curis Transfer Agreement in full force and effect. Micromet will immediately notify Enzon, and
provide copies of all communications, if Curis makes any claim or demand for reassignment to Curis
of any or all of the patents that were the subject of the Curis Transfer Agreement.

     5.3 Creative BioMolecules. Micromet represents and warrants that it is the assignee of Curis,
Inc. The Parties understand that Curis, Inc. is the successor of Creative BioMolecules, Inc. with
respect to the Curis Cross-License Agreements, and that the Parties have full power and authority
to terminate such agreements.

     5.4 DISCLAIMER OF WARRANTY. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTIONS 5.1, 5.2,
AND 5.3, ENZON AND MICROMET MAKE NO REPRESENTATIONS AND GRANT NO WARRANTIES, EXPRESS OR IMPLIED,
EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND ENZON AND MICROMET EACH
SPECIFICALLY DISCLAIM ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED,
INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR
ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY
RIGHTS OF THIRD PARTIES.

6. Confidentiality 

     6.1
Definition. “Confidential Information” means any scientific and manufacturing information
and plans; marketing and business plans; and financial and personnel matters relating to a Party or
its present or future products, sales, suppliers, customers, employees, investors or business
disclosed by one Party to the other pursuant to this Agreement.

     6.2 Exclusions.

          6.2.1 Notwithstanding the foregoing, information of a Party will not be deemed Confidential
Information with respect to a receiving Party for purposes of this Agreement if such information:

               (a) was already known to the receiving Party or its Affiliates, other than under an obligation
of confidentiality or non-use, at the time of disclosure to the receiving Party;

11

 

               (b) was generally available or known to parties reasonably skilled in the field to which such
information or know-how pertains, or was otherwise part of the public domain, at the time of its
disclosure to the receiving Party;

               (c) became generally available or known to parties reasonably skilled in the field to which
such information or know-how pertains, or otherwise became part of the public domain, after its
disclosure to the receiving Party through no fault of or breach of its obligations under this
section 6 by the receiving Party;

               (d) was disclosed to the receiving Party other than under an obligation of confidentiality or
non-use, by a Third Party who had no obligation to the Party that Controls such information and
know-how not to disclose such information or know-how to others; or

               (e) was independently discovered or developed by the receiving Party or its Affiliates, as
evidenced by their written records, without the use of, and by personnel who had no access to,
Confidential Information belonging to the Party that Controls such information and know-how.

          6.2.2 Specific aspects or details of Confidential Information will not be deemed to be within
the public domain or in the possession of a Party merely because the Confidential Information is
embraced by more general information in the public domain or in the possession of such Party.
Further, any combination of Confidential Information will not be considered in the public domain or
in the possession of a Party merely because individual elements of such Confidential Information
are in the public domain or in the possession of such Party unless the combination and its
principles are in the public domain or in the possession of such Party.

     6.3 Disclosure and Use Restriction. Except as expressly provided herein, the Parties agree
that, for the Term and for [***] thereafter, each Party and its Affiliates and sublicensees will
keep completely confidential and will not publish or otherwise disclose and will not use for any
purpose except for the purposes contemplated by this Agreement any Confidential Information of the
other Party, its Affiliates or sublicensees.

     6.4 Authorized Disclosure. Each Party may disclose Confidential Information of the other
Party to the extent that such disclosure is:

          6.4.1 made in response to a valid order of a court of competent jurisdiction or other
governmental or regulatory body of competent jurisdiction; provided, however, that
such Party will first have given notice to such other Party and given such other Party a reasonable
opportunity to quash such order and to obtain a protective order requiring that the Confidential
Information and documents that are the subject of such order be held in confidence by such court or
governmental or regulatory body or, if disclosed, be used only for the purposes for which the order
was issued; and provided, further, that if a disclosure order is not quashed or a
protective order is not obtained, the Confidential Information disclosed in response to such court
or governmental order will be limited to that information which is legally required to be disclosed
in response to such court or governmental order;

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

12

 

          6.4.2 otherwise required by law; provided, however, that the disclosing Party
will provide such other Party with notice of such disclosure in advance thereof to the extent
practicable;

          6.4.3 made by such Party to the regulatory authorities as required in connection with any
filing of BLAs, marketing approval applications, or similar applications or requests for regulatory
approvals; provided, however, that reasonable measures will be taken to assure
confidential treatment of such information;

          6.4.4 made by such Party, in connection with the performance of this Agreement, to Affiliates,
permitted sublicensees, research parties, employees, consultants, representatives or agents, each
of whom prior to disclosure must be bound by obligations of confidentiality and non-use at least
equivalent in scope to those set forth in this section 6; or

          6.4.5 made by such Party to existing or potential acquirers or merger candidates; existing or
potential pharmaceutical collaborators (to the extent contemplated hereunder); investment bankers;
existing or potential investors, venture capital firms or other financial institutions or investors
for purposes of obtaining financing; or Affiliates, each of whom prior to disclosure must be bound
by obligations of confidentiality and non-use at least equivalent in scope to those set forth in
this section 6. Notwithstanding this section 6.4.5, neither Party will disclose any item of the
other Party’s Confidential Information to any existing or potential acquirer or merger partner that
is substantially involved in the Exploitation of Single Chain Antibodies without first providing
such other Party with reasonable advance written notice of each such disclosure.

     6.5 Use of Name. Neither Party will make public use of the other Party’s name except (a) in
connection with announcements and other permitted disclosures relating to this Agreement and the
activities contemplated hereby, (b) as required by applicable law, and (c) otherwise as agreed in
writing by such other Party.

     6.6 Press Releases.

          6.6.1 With respect to any press releases and other written public disclosures relating to this
Agreement or the Parties’ relationship hereunder (“Proposed Disclosures”), each Party will use
reasonable efforts to submit to the other Party a draft of such Proposed Disclosures for review and
comment by the other Party at least [***] prior to the date on which such Party plans to release
such Proposed Disclosure, and in any event will submit such drafts at least [***] prior to the
release of such Proposed Disclosure, and will review and consider in good faith any comments
provided in response.

          6.6.2 If a Party is unable to comply with the foregoing [***] notice requirement because of a
legal obligation or stock exchange requirement to make more rapid disclosure, such Party will not
be in breach of this Agreement but will in that case give telephone notice to a senior executive of
the other Party and provide a draft disclosure with as much notice as possible prior to the release
of such Proposed Disclosure.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

13

 

          6.6.3 A Party may publicly disclose without regard to the preceding requirements of this
section 6.6 information that was previously disclosed in a Proposed Disclosure that was in
compliance with such requirements.

          6.6.4 The requirements of this section 6.6 will not apply to public disclosures, written or
otherwise regarding a Party’s Pipeline Products or Third Party Collaboration Products that do not
specifically refer to this Agreement or the Parties’ relationship hereunder.

     6.7 Terms of Agreement to be Maintained in Confidence. Subject to the provisions of this
section 6, including the exception for any public disclosures made in compliance with the terms of
section 6.6, the Parties agree that the terms of this Agreement are confidential and will not be
disclosed by either Party to any Third Party (except to a Party’s professional advisor) without
advance written permission of the other Party; provided, that either Party may make any
filings of this Agreement required by law or regulation in any country so long as such Party uses
its reasonable efforts to obtain confidential treatment for portions of this Agreement as
available, consults with the other Party, and permits the other Party to participate, to the extent
practicable, in seeking a protective order or other confidential treatment; and provided,
further, that either Party may disclose the terms of this Agreement to a Third Party (and
its professional advisors) when such disclosure is reasonably necessary in connection with (i) the
grant of a license or sublicense of the licensed Patents to such Third Party, (ii) a merger,
acquisition, placement, investment, or other such transaction with such Third Party, or (iii) the
sale of securities to or other financing from such Third Party or a financing underwritten by such
Third Party, in which case disclosure may be made to any person or entity to whom such Third Party
sells such securities (and its professional advisers). Advance written permission for disclosure
will not be required when a Party is ordered to disclose information concerning the Agreement by a
competent tribunal or such disclosures are required by law, regulation, or stock exchange rules,
except that such Party will make all reasonable efforts to limit any disclosure as may be required
in the course of legal proceedings by entry of an appropriate protective and confidentiality order,
and will provide the other Party with as much advance notice of such circumstances as is
practicable.

7. Term and Termination

     7.1 Term. This Agreement is effective as of the Effective Date and will expire upon the
expiration of the last to expire Patent within the Consolidated Patent Portfolio (the “Term”).

     7.2 Termination for Material Breach.

          7.2.1 Any material failure by a Party to comply with any of its material obligations contained
herein (“Default”) will entitle the Party not in default to give to the Party in Default written
notice specifying the nature of the Default, requiring the defaulting Party to make good or
otherwise cure such Default.

          7.2.2 If such Default is not cured within [***] after the receipt of notice pursuant to
section 7.2.1 above (or, if such Default cannot be cured within such [***] period, if

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

14

 

the Party in Default does not commence actions to cure such Default within such [***] period
and thereafter diligently continue such actions or if such Default is not otherwise cured within
[***]after the receipt of such notice, except in the case of a payment Default, as to which the
defaulting Party will have only a [***] cure period), the Party not in Default will be entitled, on
written notice to the other Party and without prejudice to any of its other rights conferred on it
by this Agreement to seek a determination by a court of competent jurisdiction, in accordance with
the procedures set forth in section 10.4 hereof, that such Default constitutes a material breach of
this Agreement for which termination of this Agreement is authorized by law (such determination a
“Finding of Justifiable Termination”).

          7.2.3 Upon a Finding of Justifiable Termination, the Party not in default will be entitled, in
addition to any other remedies available to it by law or in equity, to terminate this Agreement,
unless the breaching Party has cured such Default within [***] after delivery of the Finding of
Justifiable Termination.

     7.3 Consequences of Expiration and Termination.

          7.3.1 For Material Breach. Upon termination of this Agreement by a Party pursuant to section
7.2, (i) all licenses granted by the terminating Party to the defaulting Party will terminate
(except as provided in section 7.3.2); (ii) the licenses granted by the defaulting Party will
survive (subject to continued performance by the terminating Party of its royalty obligations, if
any); and (iii) the milestone and royalty obligations set forth in section 3 with respect to the
surviving licenses will continue.

          7.3.2 Survival of Certain Sublicenses. Sublicenses granted by a defaulting Party to a Third
Party will survive termination of the defaulting Party’s license under section 7.3.1(i);
provided, that (x) such Third Party is not the cause of the default, (y) such Third Party
is not in breach of, and continues to fully perform all obligations under, its sublicense
agreement, and (z) the terminating Party continues to receive from such Third Party all royalty and
milestone payments set forth in section 3.1 due on account of Net Sales of Licensed Products by
such Third Party.

          7.3.3 Obligations Continue. Expiration or termination of this Agreement will not relieve the
Parties of any obligation accruing prior to such expiration or termination. The provisions of
sections 2.2.3, 3.1.4, 3.2.3 to 3.2.8, 5.4, 6 (except 6.6), 7.3, 8, 9 and 10 will survive
termination or expiration of this Agreement.

8. Indemnification and Insurance

     8.1 Indemnification of Micromet. Enzon will indemnify Micromet, its Affiliates, and their
respective directors, officers, employees and agents, and defend and save each of them harmless,
from and against any and all losses, damages, liabilities, costs and expenses (including reasonable
attorneys’ fees and expenses) in connection with any and all liability suits, investigations,
claims or demands (collectively, “Losses”) by Third Parties arising from or

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

15

 

occurring as a result of or in connection with Exploitation by Enzon of Licensed Products
under the Micromet License.

     8.2 Indemnification of Enzon. Micromet will indemnify Enzon, its Affiliates, and their
respective directors, officers, employees and agents, and defend and save each of them harmless,
from and against any and all Losses by Third Parties arising from or occurring as a result of or in
connection with Exploitation by Micromet of Licensed Products under the Enzon License, including
any claims of Curis, Inc. for payment of license fees or royalties in connection with such
Exploitation.

     8.3 Indemnification Procedure.

          8.3.1 Notice of Claim. The indemnified Party will give the indemnifying Party (the
“Indemnifying Party”) prompt written notice (an “Indemnification Claim Notice”) of any Losses or
discovery of fact upon which such Indemnified Party intends to base a request for indemnification
under section 8.1 or section 8.2, but in no event will the Indemnifying Party be liable for any
Losses that result from any delay in providing such notice. Each Indemnification Claim Notice must
contain a description of the claim and the nature and amount of such Loss (to the extent that the
nature and amount of such Loss are known at such time). The indemnified Party will furnish
promptly to the indemnifying Party copies of all papers and official documents received in respect
of any Losses. All indemnification claims in respect of a Party, its Affiliates or their
respective directors, officers, employees and agents (collectively, the “Indemnitees” and each an
“Indemnitee”) will be made solely by such Party to this Agreement (the “Indemnified Party”).

          8.3.2 Third Party Claims. The obligations of an Indemnifying Party under this section 8 with
respect to Losses arising from claims of any Third Party that are subject to indemnification as
provided for in section 8.1 or 8.2 (a “Third Party Claim”) will be governed by and be contingent
upon the following additional terms and conditions:

               (a) Control of Defense.

                    (i) At its option, the Indemnifying Party may assume the defense of any Third Party Claim by
giving written notice to the Indemnified Party within 30 days after the Indemnifying Party’s
receipt of an Indemnification Claim Notice.

                    (ii) Upon assuming the defense of a Third Party Claim, the Indemnifying Party may appoint as
lead counsel in the defense of the Third Party Claim any legal counsel selected by the Indemnifying
Party. In the event the Indemnifying Party assumes the defense of a Third Party Claim, the
Indemnified Party will immediately deliver to the Indemnifying Party all original notices and
documents (including court papers) received by any Indemnitee in connection with the Third Party
Claim. Should the Indemnifying Party assume the defense of a Third Party Claim, the Indemnifying
Party will not be liable to the Indemnified Party or any other Indemnitee for any legal expenses
subsequently incurred by such Indemnified Party or other Indemnitee in connection with the
analysis, defense or settlement of the Third Party Claim.

16

 

               (b) Right to Participate in Defense. Without limiting section 8.3.2(a), any Indemnitee will
be entitled to participate in, but not control, the defense of such Third Party Claim and to employ
counsel of its choice for such purpose; provided, however, that such employment
will be at the Indemnitee’s own expense unless (i) the employment thereof has been specifically
authorized by the Indemnifying Party in writing, or (ii) the Indemnifying Party has failed to
assume the defense and employ counsel in accordance with section 8.3.2(a) (in which case the
Indemnified Party will control the defense).

               (c) Settlement. With respect to any Losses relating solely to the payment of money damages in
connection with a Third Party Claim and that will not result in the Indemnitee’s becoming subject
to injunctive or other relief or otherwise adversely affect the business of the Indemnitee in any
manner, and as to which the Indemnifying Party will have acknowledged in writing the obligation to
indemnify the Indemnitee hereunder, the Indemnifying Party will have the sole right to consent to
the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such
terms as the Indemnifying Party, in its sole discretion, will deem appropriate, and will transfer
to the Indemnified Party all amounts which said Indemnified Party will be liable to pay prior to
the time prior to the entry of judgment. With respect to all other Losses in connection with Third
Party Claims, where the Indemnifying Party has assumed the defense of the Third Party Claim in
accordance with section 8.3.2(a), the Indemnifying Party will have authority to consent to the
entry of any judgment, enter into any settlement or otherwise dispose of such Loss provided it
obtains the prior written consent of the Indemnified Party (which consent will be at the
Indemnified Party’s sole and absolute discretion). The Indemnifying Party will not be liable for
any settlement or other disposition of a Loss by an Indemnitee that is reached without the written
consent of the Indemnifying Party. Regardless of whether the Indemnifying Party chooses to defend
or prosecute any Third Party Claim, no Indemnitee will admit any liability with respect to, or
settle, compromise or discharge, any Third Party Claim without the prior written consent of the
Indemnifying Party.

               (d) Cooperation. Regardless of whether the Indemnifying Party chooses to defend or prosecute
any Third Party Claim, the Indemnified Party will, and will cause each other Indemnitee to,
cooperate in the defense or prosecution thereof and will furnish such records, information and
testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings,
trials and appeals as may be reasonably requested in connection therewith. Such cooperation will
include access during normal business hours afforded to the Indemnifying Party to, and reasonable
retention by the Indemnified Party of, records and information that are reasonably relevant to such
Third Party Claim, and making Indemnitees and other employees and agents available on a mutually
convenient basis to provide additional information and explanation of any material provided
hereunder, and the Indemnifying Party will reimburse the Indemnified Party for all its reasonable
out-of-pocket expenses in connection therewith.

     8.4 Expenses. Except as provided above, the reasonable and verifiable costs and expenses,
including fees and disbursements of counsel, incurred by the Indemnified Party in connection with
any claim will be reimbursed on a calendar quarter basis by the Indemnifying Party, without
prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to
indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to
be obligated to indemnify the Indemnified Party.

17

 

     8.5 Insurance. Each Party will have and maintain such types and amounts of liability
insurance as is normal and customary in the industry generally for parties similarly situated, and
will upon request provide the other Party with a copy of its policies of insurance in that regard,
along with any amendments and revisions thereto.

9. Limitation of Liability

     IN NO EVENT WILL EITHER PARTY BE LIABLE FOR LOST PROFITS, LOSS OF DATA, OR FOR ANY SPECIAL,
INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY
AND WHETHER OR NOT SUCH PARTY HAD OR SHOULD HAVE HAD KNOWLEDGE, ACTUAL OR CONSTRUCTIVE, OF THE
POSSIBILITY OF SUCH DAMAGES, ARISING UNDER ANY CAUSE OF ACTION AND ARISING IN ANY WAY OUT OF THIS
AGREEMENT. THE FOREGOING LIMITATIONS WILL NOT APPLY TO AN AWARD OF ENHANCED DAMAGES AVAILABLE
UNDER THE PATENT LAWS FOR WILLFUL PATENT INFRINGEMENT AND WILL NOT LIMIT EITHER PARTY’S INDEMNITY
OBLIGATIONS TO THE OTHER PARTY UNDER THIS AGREEMENT. The foregoing limitations on liability and
exclusions of damages: (a) are a fundamental element of the basis of the bargain between the
Parties and this Agreement would not be entered into without such limitations and exclusions; and
(b) shall apply notwithstanding any failure of essential purpose of any limited remedy herein.

10. Miscellaneous

     10.1 Rights in Bankruptcy. All rights and licenses granted under or pursuant to this
Agreement by Micromet or Enzon are, and will otherwise be deemed to be, for purposes of Section
365(n) of the United States Bankruptcy Code, licenses of rights to “intellectual property” as
defined under Section 101 of the United States Bankruptcy Code except as may otherwise be required
by any provision under German insolvency laws. The Parties agree that the Parties, as licensees of
such rights under this Agreement, will retain and may fully exercise all of their rights and
elections under the United States Bankruptcy Code to the extent not otherwise required under German
insolvency laws. The Parties further agree that, in the event of the commencement of a bankruptcy
proceeding by or against a Party under the United States Bankruptcy Code, or the German Insolvency
Act (Insolvenzordnung), as the case may be, the Party hereto that is not a Party to such proceeding
will be entitled to a complete duplicate of (or complete access to, as appropriate) any such
intellectual property and all embodiments of such intellectual property, which, if not already in
the non-subject Party’s possession, will be promptly delivered to it (a) upon any such commencement
of a bankruptcy proceeding upon the non-subject Party’s written request therefore, unless the Party
subject to such proceeding continues to perform all of its obligations under this Agreement or (b)
if not delivered under clause (a) above, following the rejection of this Agreement by or on behalf
of the Party subject to such proceeding upon written request therefore by the non-subject Party.

     10.2 Assignment. Without the prior written consent of the other Party hereto (which such
consent may be granted, withheld or conditioned at the other Party’s sole and absolute discretion),
neither Party will sell, transfer, assign, delegate, pledge or otherwise dispose of, whether
voluntarily, involuntarily, by operation of law or otherwise, this Agreement or any of its

18

 

rights or duties hereunder; provided, however, that either Party hereto may
assign or transfer this Agreement or any of its rights or obligations hereunder without the consent
of the other Party (a) to any Affiliate of such Party; or (b) to any Third Party with which it
merges or consolidates, or to which it transfers all or substantially all of its assets to which
this Agreement relates, and provided, further, in either case that such assignment
may occur only together with a permitted assignment of both the Collaboration Agreement (if then in
force) and the Marketing Agreement (if then in force) to such assignee. The assigning Party
(except if it is not the surviving entity) will remain jointly and severally liable with the
relevant Affiliate or Third Party assignee under this Agreement, and the relevant Affiliate
assignee, Third Party assignee or surviving entity will assume in writing all of the assigning
Party’s obligations under this Agreement. Any purported assignment or transfer in violation of
this section will be void ab initio and of no force or effect.

     10.3 Severability. If any provision of this Agreement is held to be illegal, invalid or
unenforceable under any present or future law, and if the rights or obligations of either Party
under this Agreement will not be materially and adversely affected thereby, (a) such provision will
be fully severable, (b) this Agreement will be construed and enforced as if such illegal, invalid
or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this
Agreement will remain in full force and effect and will not be affected by the illegal, invalid or
unenforceable provision or by its severance herefrom, and (d) in lieu of such illegal, invalid or
unenforceable provision, there will be added automatically as a part of this Agreement a legal,
valid and enforceable provision as similar in terms to such illegal, invalid or unenforceable
provision as may be possible and reasonably acceptable to the Parties herein. To the fullest
extent permitted by applicable law, each Party hereby waives any provision of law that would render
any provision prohibited or unenforceable in any respect.

     10.4 Governing Law; Dispute Resolution.

          10.4.1 This Agreement, its interpretation and construction, and any controversy, claim or
dispute between the Parties related to or arising out of this Agreement or the Original License
Agreement (each a “Dispute”), including any Dispute relating to the Parties’ relationship created
hereby, the negotiations for and entry into this Agreement or the Original License Agreement, its
conclusion, binding effect, amendment, coverage, or termination, or the performance or alleged
non-performance of a Party of its obligations under this Agreement or the Original License
Agreement, will be governed by the laws of the State of New York applicable to contracts made and
wholly performed within such jurisdiction by residents of such jurisdiction and without reference
to its choice of law principles.

          10.4.2 The Parties will try to settle any Dispute amicably between themselves. In the event
of a Dispute, a Party may notify the other Party in writing of such Dispute. If the Parties are
unable to resolve the Dispute within [***] of receipt of the written notice by the other Party,
such dispute will be referred to the [***] who will use their good faith efforts to resolve the
Dispute within [***] after it was referred to the [***].

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

19

 

          10.4.3 If a Dispute is not resolved [***] pursuant to section 10.4.2, either Party may bring
an action in the federal courts or State courts located in New York County, State of New York,
which will have exclusive jurisdiction (without prejudice to the right to seek removal to federal
courts) over any such Disputes. The Parties submit to the personal jurisdiction of such courts for
any such action, agree that such courts provide a convenient forum for any such action, and waive
any objections or challenges to venue.

     10.5 Notices. All notices or other communications that are required or permitted hereunder
will be in writing and delivered personally, sent by facsimile (and promptly confirmed by personal
delivery or overnight courier as provided herein), or sent by internationally-recognized overnight
courier addressed as follows:

     If to Enzon, to:

Enzon Pharmaceuticals, Inc.

685 Route 202/206

Bridgewater, New Jersey 08807

USA

Attention: Chief Executive Officer

Facsimile: (908) 575-1843

with a copy to:

Enzon Pharmaceuticals, Inc.

685 Route 202/206

Bridgewater, NJ 08807

Attention: General Counsel

Facsimile: (908) 541-8838

and

Kenyon & Kenyon

One Broadway

New York, NY 10004-1050

Attention: Charles A. Weiss, Esq.

Facsimile: (212) 425-5288

     If to Micromet, to:

Micromet AG

Staffelseestrasse 2

81477 Munich

Germany

Attention: Chief Executive Officer

Facsimile: ++49 89 895-277 285

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

20

 

with a copy to:

Cooley Godward LLP

One Freedom Square

Reston Town Center

11951 Freedom Drive

Reston, Virginia 20190-5656

Attention: Matthias Alder, Esq.

Facsimile: (703) 456-8100

or to such other address as the Party to whom notice is to be given may have furnished to the other
Party in writing in accordance herewith. Any such communication will be deemed to have been given
(i) when delivered, if personally delivered or sent by facsimile on a business day, and (ii) on the
second business day after dispatch, if sent by internationally-recognized overnight courier. It is
understood and agreed that this section 10.5 is not intended to govern the day-to-day business
communications necessary between the Parties in performing their duties, in due course, under the
terms of this Agreement.

     10.6 Entire Agreement; Modifications. This Agreement sets forth and constitutes the entire
agreement and understanding between the Parties with respect to the subject matter hereof and all
prior agreements, understanding, promises and representations, whether written or oral, with
respect thereto, including without limitation, the Curis Cross-License Agreements and the Original
License Agreement, are superseded hereby. Each Party confirms that it is not relying on any
representations or warranties of the other Party except as specifically set forth herein. No
amendment or modification of this Agreement will be binding upon the Parties unless made in writing
and duly executed by authorized representatives of both Parties.

     10.7 Relationship of the Parties. It is expressly agreed that the Parties’ relationship under
this Agreement is strictly one of licensor-licensee, and that this Agreement does not create or
constitute a partnership, joint venture, or agency. Neither Party will have the authority to make
any statements, representations or commitments of any kind, or to take any action, which will be
binding (or purport to be binding) on the other. All persons employed by a Party will be employees
of such Party and not of the other Party and all costs and obligations incurred by reason of any
such employment will be for the account and expense of such Party.

     10.8 Waiver. Any term or condition of this Agreement may be waived at any time by the Party
that is entitled to the benefit thereof, but no such waiver will be effective unless set forth in a
written instrument duly executed by or on behalf of the Party waiving such term or condition. The
waiver by either Party hereto of any right hereunder or of claims based on the failure to perform
or a breach by the other Party will not be deemed a waiver of any other right hereunder or of any
other breach or failure by said other Party whether of a similar nature or otherwise.

     10.9 Counterparts. This Agreement may be executed in 2 or more counterparts, each of which
will be deemed an original, but all of which together will constitute one and the same instrument.

21

 

     10.10 No Benefit to Third Parties. The representations, warranties, covenants and agreements
set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and
permitted assigns, and they will not be construed as conferring any rights on any other parties.

     10.11 Further Assurance. Each Party will duly execute and deliver, or cause to be duly
executed and delivered, such further instruments and do and cause to be done such further acts and
things, including the filing of such assignments, agreements, documents and instruments, as may be
necessary or as the other Party may reasonably request in connection with this Agreement or to
carry out more effectively the provisions and purposes, or to better assure and confirm unto such
other Party its rights and remedies under this Agreement.

     10.12 English Language. This Agreement has been written and executed in the English language.
Any translation into any other language will not be an official version thereof, and in the event
of any conflict in interpretation between the English version and such translation, the English
version will control.

     10.13 Construction. Except where the context otherwise requires, wherever used, the singular
will include the plural, the plural the singular, the use of any gender will be applicable to all
genders and the word “or” is used in the inclusive sense (and/or). The captions of this Agreement
are for convenience of reference only and in no way define, describe, extend or limit the scope or
intent of this Agreement or the intent of any provision contained in this Agreement. The term
“including” as used herein means including, without limiting the generality of any description
preceding such term. The language of this Agreement will be deemed to be the language mutually
chosen by the Parties and no rule of strict construction will be applied against either Party
hereto.

[Remainder of Page Intentionally Left Blank]

22

 

     In Witness Whereof, the Parties
have caused this Agreement to be executed by their authorized representatives as of the Amendment
Date.

	 	 	 	 	 	 	 	 	 
	 

	 	Micromet AG
	 	 	 	 	 	Enzon Pharmaceuticals, Inc.
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Christian Itin
	 	 	 	By:
	 	/s/ Kenneth J. Zuerblis
	Name:

	 	Christian Itin
	 	 	 	Name:
	 	Kenneth J. Zuerblis
	Title:

	 	CEO
	 	 	 	Title:
	 	Vice President, Finance, Chief Financial Officer and Corporate Secretary
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Patrick Baeuerle	 	 	 	 	 	 
	Name:

	 	Patrick Baeuerle	 	 	 	 	 	 
	Title:

	 	CSO	 	 	 	 	 	 

 

 

[Signature Page to the Amended and Restated Cross-License Agreement]

2.

 

Appendix A

Enzon Licensed Patents

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Application	 	Application	 	 	 	 	 	 	 	Patent	 	Date of
	Number	 	Filing Date	 	Country	 	Title of Application	 	Status	 	Number	 	Grant
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

3.

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Application	 	Application	 	 	 	 	 	 	 	Patent	 	Date of
	Number	 	Filing Date	 	Country	 	Title of Application	 	Status	 	Number	 	Grant
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

4.

 

Appendix B

Micromet Licensed Patents

     [***][***]

	 	 	 	 	 	 	 	 	 	 	 
	Country	 	Serial #	 	Filed	 	Patent #	 	Inventors	 	Title
	[***]
	 	[***]
	 	[***]	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]
	 	[***]
	 	[***]
	 	 	 	[***]	 	 
	[***]
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]
	 	 	 	[***]
	 	[***]
	 	[***]	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]
	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]
	 	
	 	
	 	 	 	
	 	

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

 

 

     Biosynthetic Antibody Binding Sites/Genetically Engineered Antibody Analogues And Fusion
Proteins Thereof

	 	 	 	 	 	 	 	 	 	 	 
	Country	 	Filed	 	Serial #	 	Patent #	 	Inventors	 	Title
	[***]
	 	[***]
	 	[***]	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]
	 	[***]
	 	[***]	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]
	 	[***]
	 	[***]	 	 	 	 	 	 

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

2.

 

     [***]

	 	 	 	 	 	 	 	 	 	 	 
	Application	 	Application	 	 	 	 
	Number	 	Filing Date	Country	Title of Application	Status	Patent Number
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 	 	 	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

 

			
	*	 	The rights granted under this Agreement do not apply to claims relating to those antibodies of
specific sequences [***], which antibodies are described or disclosed in the above-described
Patents, and such claims are excluded from the definition of the Micromet Licensed Patents.

     [***][***]

	 	 	 	 	 	 	 	 	 	 	 
	Country	 	Filed	 	Serial #	 	Patent #	 	Inventors	 	Title
	[***]
	 	[***]
	 	[***]	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]
	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	 	[***]
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]
	 	 	 	 	 	 	 	 	 	 

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

3.

 

     [***]

	 	 	 	 	 	 	 	 	 	 	 
	Country	 	Filed	 	Serial #	 	Patent #	 	Inventors	 	Title
	[***]
	 	[***]
	 	[***]	 	 	 	 	 	 
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

4.

 

Appendix C

Field Limitations

[***]

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

 

 

Exhibit 10.39

***Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

AMENDMENT

TO

AMENDED AND RESTATED CROSS-LICENSE AGREEMENT

     This Amendment (the “Amendment") is made as of this 17th day of March, 2005 by and
between Micromet AG, located at Staffelseestrasse 2, D-81477, Munich, Germany
(“Micromet"), and Enzon Pharmaceuticals Inc., located at 685 Route 202/206, Bridgewater,
New Jersey 08807, USA (“Enzon”) (each of Micromet and Enzon, a “Party” and, collectively, the
“Parties”).

Recitals

     A. The Parties have entered into that certain Amended and Restated Cross-License Agreement,
dated as of June 28, 2004 (the “Agreement"), pursuant to which the Parties have granted certain
intellectual property licenses for the purposes described therein. Capitalized terms used herein
without definition shall have the meanings given to such terms in the Agreement.

     B. The Parties desire to amend the Agreement to include an additional licensed patent of Enzon
thereunder.

Agreement

     Now, Therefore, for and in consideration of the mutual promises and covenants set
forth herein and for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the Parties hereby agree as follows:

     1. Amendment to Appendix A. The Parties hereby agree to amend Appendix A of the Agreement by
appending the following at the end of such Appendix: “[***],’ issued [***]. The rights granted to
such patent under this Agreement are solely in the field of manufacture, use or sale of Single
Chain Antibodies.”

     2. Counterparts. This Amendment may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same
instrument.

     3. Effectiveness. This Amendment shall become effective upon the execution hereof by both
Parties.

     4. Continuing Effect. Other than as set forth in this Amendment, all of the terms and
conditions of the Agreement shall continue in full force and effect.

 

			
	***	 	Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

1.

 

     In Witness Whereof, the parties have executed this Amendment to Amended and Restated
Cross-License Agreement as of the date first written above.

	 	 	 	 
	Micromet AG

	 	Enzon Pharmaceuticals, Inc.	
	 
	 	 	
	By:
/s/ Christian Itin

	 	By: /s/ Jeffrey H. Buchalter	
	 
	 	
 

	
	 
	 	 	
	Name: Christian Itin

	 	Name: Jeffrey H. Buchalter	
	 
	 	 	
	Title: CEO

	 	Title: Chairman, President & CEO	

2.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]